Document and Entity Information
Document and Entity Information - shares | 3 Months Ended | |
Mar. 31, 2019 | May 07, 2019 | |
Document And Entity Information [Abstract] | ||
Document Type | 10-Q | |
Amendment Flag | false | |
Document Period End Date | Mar. 31, 2019 | |
Document Fiscal Year Focus | 2019 | |
Document Fiscal Period Focus | Q1 | |
Trading Symbol | AVDR | |
Entity Registrant Name | AVEDRO INC | |
Entity Central Index Key | 0001343304 | |
Current Fiscal Year End Date | --12-31 | |
Entity Filer Category | Non-accelerated Filer | |
Entity Small Business | true | |
Entity Emerging Growth Company | true | |
Entity Ex Transition Period | false | |
Entity Common Stock, Shares Outstanding | 17,110,068 |
Condensed Consolidated Balance
Condensed Consolidated Balance Sheets - USD ($) $ in Thousands | Mar. 31, 2019 | Dec. 31, 2018 |
Current assets: | ||
Cash and cash equivalents | $ 64,809 | $ 9,769 |
Accounts receivable (including $645 and $573 from related parties as of March 31, 2019 and December 31, 2018, net of allowance of $183 and $198, respectively) | 10,973 | 4,725 |
Inventories | 4,473 | 4,259 |
Prepaid expenses and other current assets | 3,116 | 1,919 |
Total current assets | 83,371 | 20,672 |
Equipment and furniture, net | 1,447 | 1,524 |
Restricted cash | 551 | 551 |
Deferred offering costs | 2,829 | |
Other assets | 380 | 291 |
Total assets | 85,749 | 25,867 |
Current liabilities: | ||
Accounts payable | 2,521 | 2,126 |
Accrued expenses and other current liabilities | 5,134 | 5,366 |
Current portion of license obligation | 250 | 250 |
Deferred revenue | 779 | 688 |
Total current liabilities | 8,684 | 8,430 |
Deferred revenue, net of current portion | 21 | 12 |
Long-term debt obligations, net of current portion | 20,128 | 19,939 |
Derivative and warrant liability | 197 | 2,206 |
Other non-current liabilities | 3 | 13 |
Deferred rent | 444 | 432 |
Total liabilities | 29,477 | 31,032 |
Commitments and contingencies (Note 6) | ||
Stockholders’ equity (deficit): | ||
Preferred stock, $0.00001 par value; 10,000,000 and zero shares authorized at March 31, 2019 and December 31, 2018, respectively; no shares issued and outstanding at March 31, 2019 and December 31, 2018 | ||
Common stock, $0.00001 par value; authorized shares 200,000,000 and 66,905,000 at March 31, 2019 and December 31, 2018, respectively; issued and outstanding shares 17,066,926 and 1,412,003 at March 31, 2019 and December 31, 2018, respectively | 2 | 2 |
Additional paid-in capital | 241,073 | 108,532 |
Accumulated deficit | (184,803) | (182,122) |
Total stockholders’ equity (deficit) | 56,272 | (73,588) |
Total liabilities, convertible preferred stock and stockholders’ equity | $ 85,749 | 25,867 |
Series AA Convertible Preferred Stock | ||
Convertible preferred stock: | ||
Convertible preferred stock | 31,852 | |
Series BB Convertible Preferred Stock | ||
Convertible preferred stock: | ||
Convertible preferred stock | 11,789 | |
Series CC Convertible Preferred Stock | ||
Convertible preferred stock: | ||
Convertible preferred stock | $ 24,782 |
Condensed Consolidated Balanc_2
Condensed Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Thousands | Mar. 31, 2019 | Dec. 31, 2018 |
Due from related parties current | $ 645 | $ 573 |
Allowance for doubtful accounts receivable | $ 183 | $ 198 |
Preferred stock, par value per share | $ 0.00001 | $ 0.00001 |
Preferred Stock, Shares Authorized | 10,000,000 | 0 |
Preferred Stock, Shares Issued | 0 | 0 |
Preferred Stock, Value, Outstanding | 0 | 0 |
Common stock, par value per share | $ 0.00001 | $ 0.00001 |
Common stock, shares authorized | 200,000,000 | 66,905,000 |
Common stock, shares issued | 17,066,926 | 1,412,003 |
Common stock, shares outstanding | 17,066,926 | 1,412,003 |
Series AA Convertible Preferred Stock | ||
Convertible preferred stock, par value per share | $ 0.00001 | $ 0.00001 |
Convertible preferred stock, shares authorized | 0 | 32,650,000 |
Convertible preferred stock, shares issued | 0 | 7,161,719 |
Convertible preferred stock, shares outstanding | 0 | 7,161,719 |
Convertible preferred stock, liquidation preference | $ 0 | |
Series BB Convertible Preferred Stock | ||
Convertible preferred stock, par value per share | $ 0.00001 | $ 0.00001 |
Convertible preferred stock, shares authorized | 0 | 5,950,000 |
Convertible preferred stock, shares issued | 0 | 1,332,708 |
Convertible preferred stock, shares outstanding | 0 | 1,332,708 |
Convertible preferred stock, liquidation preference | $ 0 | |
Series CC Convertible Preferred Stock | ||
Convertible preferred stock, par value per share | $ 0.00001 | $ 0.00001 |
Convertible preferred stock, shares authorized | 0 | 9,529,571 |
Convertible preferred stock, shares issued | 0 | 2,141,467 |
Convertible preferred stock, shares outstanding | 0 | 2,141,467 |
Convertible preferred stock, liquidation preference | $ 0 |
Condensed Statements of Operati
Condensed Statements of Operations (Unaudited) - USD ($) $ in Thousands | 3 Months Ended | |
Mar. 31, 2019 | Mar. 31, 2018 | |
Income Statement [Abstract] | ||
Revenue (including related party activity of $580 and $512 for the three months ended March 31, 2019 and 2018, respectively) | $ 8,773 | $ 5,154 |
Cost of goods sold (including related party activity of $112 and $126 for the three months ended March 31, 2019 and 2018, respectively) | 2,284 | 2,618 |
Gross profit | 6,489 | 2,536 |
Operating expenses: | ||
Selling, general and administrative | 10,221 | 5,288 |
Research and development | 4,285 | 2,954 |
Total operating expenses | 14,506 | 8,242 |
Loss from operations | (8,017) | (5,706) |
Other income (expense): | ||
Interest income | 195 | 6 |
Interest expense | (700) | (627) |
Other (expense) income, net | 169 | (307) |
Total other (expense) income, net | (336) | (928) |
Net loss | $ (8,353) | $ (6,634) |
Net loss per share of common stock, basic and diluted | $ (1) | $ (4.85) |
Weighted average shares of common stock used to compute net loss per share, basic and diluted | 8,368,839 | 1,367,914 |
Condensed Statements of Opera_2
Condensed Statements of Operations (Parenthetical) (Unaudited) - USD ($) $ in Thousands | 3 Months Ended | |
Mar. 31, 2019 | Mar. 31, 2018 | |
Income Statement [Abstract] | ||
Revenue from Related Parties | $ 580 | $ 512 |
Related Party costs | $ 112 | $ 126 |
Condensed Statements of Convert
Condensed Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit) - USD ($) $ in Thousands | Total | Series AA Convertible Preferred Stock | Series BB Convertible Preferred Stock | Series CC Convertible Preferred Stock | Common Stock | Additional Paid-In Capital | Accumulated Deficit |
Beginning balance, shares at Dec. 31, 2017 | 1,363,050 | ||||||
Beginning balance at Dec. 31, 2017 | $ (49,520) | $ 2 | $ 107,478 | $ (157,000) | |||
Temporary equity, beginning balance, shares at Dec. 31, 2017 | 7,161,719 | 1,332,708 | |||||
Temporary equity, beginning balance at Dec. 31, 2017 | $ 31,852 | $ 11,789 | |||||
Exercise of common stock options | 54 | 54 | |||||
Exercise of common stock options, shares | 39,465 | ||||||
Share-based compensation | 406 | 406 | |||||
Net loss | (6,634) | (6,634) | |||||
Ending balance, shares at Mar. 31, 2018 | 1,402,515 | ||||||
Ending balance at Mar. 31, 2018 | (55,694) | $ 2 | 107,938 | (163,634) | |||
Temporary equity, ending balance, shares at Mar. 31, 2018 | 7,161,719 | 1,332,708 | |||||
Temporary equity, ending balance at Mar. 31, 2018 | $ 31,852 | $ 11,789 | |||||
Beginning balance, shares at Dec. 31, 2018 | 1,412,003 | ||||||
Beginning balance at Dec. 31, 2018 | (73,588) | $ 2 | 108,532 | (182,122) | |||
Temporary equity, beginning balance, shares at Dec. 31, 2018 | 7,161,719 | 1,332,708 | 2,141,467 | ||||
Temporary equity, beginning balance at Dec. 31, 2018 | $ 31,852 | $ 11,789 | $ 24,782 | ||||
Exercise of common stock options | $ 8 | 8 | |||||
Exercise of common stock options, shares | 2,985 | 2,985 | |||||
Share-based compensation | $ 1,250 | 1,250 | |||||
Issuance of common stock in connection with initial public offering, net of issuance costs | 61,025 | 61,025 | |||||
Issuance of common stock in connection with initial public offering, net of issuance costs, shares | 5,000,000 | ||||||
Conversion of convertible preferred stock into common stock, shares | 10,635,894 | ||||||
Conversion of convertible preferred stock into common stock | 68,423 | 68,423 | |||||
Temporary equity, conversion of convertible preferred stock into common stock, shares | (7,161,719) | (1,332,708) | (2,141,467) | ||||
Temporary equity, conversion of convertible preferred stock into common stock | $ (31,852) | $ (11,789) | $ (24,782) | ||||
Reclassification of a warrant to purchase shares of convertible preferred stock into a warrant to purchase common stock | 1,835 | 1,835 | |||||
Vesting of restricted stock units | 13,892 | ||||||
Exercise of common stock warrant | 2,152 | ||||||
Net loss | (8,353) | (8,353) | |||||
Ending balance, shares at Mar. 31, 2019 | 17,066,926 | ||||||
Ending balance at Mar. 31, 2019 | 56,272 | $ 2 | $ 241,073 | (184,803) | |||
Temporary equity, ending balance, shares at Mar. 31, 2019 | 0 | 0 | 0 | ||||
Cumulative effect of accounting change | $ 5,672 | $ 5,672 |
Condensed Statements of Conve_2
Condensed Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit) (Parenthetical) - USD ($) $ in Thousands | 3 Months Ended | ||
Mar. 31, 2019 | Dec. 31, 2018 | Mar. 31, 2018 | |
Issuance Costs | $ 8,975 | ||
Common stock, par value per share | $ 0.00001 | $ 0.00001 | $ 0.00001 |
Series AA Convertible Preferred Stock | |||
Convertible preferred stock, par value per share | 0.00001 | 0.00001 | 0.00001 |
Series BB Convertible Preferred Stock | |||
Convertible preferred stock, par value per share | 0.00001 | 0.00001 | 0.00001 |
Series CC Convertible Preferred Stock | |||
Convertible preferred stock, par value per share | $ 0.00001 | $ 0.00001 | $ 0.00001 |
Condensed Statements of Cash Fl
Condensed Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands | 3 Months Ended | |
Mar. 31, 2019 | Mar. 31, 2018 | |
CASH FLOWS FROM OPERATING ACTIVITIES: | ||
Net loss | $ (8,353) | $ (6,634) |
Adjustments to reconcile net loss to net cash used in operating activities: | ||
Depreciation | 174 | 169 |
Noncash interest expense | 189 | 127 |
Change in assets and liabilities held at fair value (Note 5) | (174) | 289 |
Bad debt expense | (15) | |
Share-based compensation | 1,250 | 406 |
Other non-cash reconciling items | 8 | |
Changes in assets and liabilities: | ||
Accounts receivable | (752) | (403) |
Prepaid expenses and other current assets | (1,019) | 628 |
Inventories | (224) | (239) |
Accounts payable and accrued expenses | 341 | 489 |
Deferred revenue | (12) | 71 |
Other non-current assets and liabilities | 48 | 17 |
Net cash used in operating activities | (8,547) | (5,072) |
CASH FLOWS FROM INVESTING ACTIVITIES: | ||
Purchase of equipment and furniture | (80) | (122) |
Net cash used in investing activities | (80) | (122) |
CASH FLOWS FROM FINANCING ACTIVITIES: | ||
Proceeds from initial public offering, net of underwriting discounts and commissions | 65,100 | |
Proceeds from the exercise of common stock options | 8 | 54 |
Initial public offering costs | (1,400) | |
Payment for asset purchase obligation | (31) | (34) |
Principal payments on capital lease obligation | (10) | (9) |
Net cash provided by financing activities | 63,667 | 11 |
Net increase (decrease) in cash, cash equivalents and restricted cash | 55,040 | (5,183) |
Cash, cash equivalents and restricted cash—Beginning of period | 10,320 | 9,401 |
Cash, cash equivalents and restricted cash—End of period | 65,360 | 4,218 |
Cash paid for interest | 511 | $ 499 |
Supplemental disclosure of non-cash investing and financing activities | ||
Conversion of convertible preferred stock to common stock | 68,423 | |
Conversion of convertible preferred stock warrants to common stock warrants | 1,835 | |
Offering costs included in accounts payable and accrued expenses | $ 1,447 |
Nature of Business and Basis of
Nature of Business and Basis of Presentation | 3 Months Ended |
Mar. 31, 2019 | |
Organization Consolidation And Presentation Of Financial Statements [Abstract] | |
Nature of Business and Basis of Presentation | 1. Nature of Business and Basis of Presentation Organization Avedro, Inc. (“Avedro” or the “Company”) was incorporated in Delaware on November 6, 2002. The Company is an ophthalmic pharmaceutical and medical device company developing and commercializing a suite of products based on its proprietary corneal collagen cross-linking technology platform (the “Avedro Cross-Linking Platform”) to address a wide variety of ophthalmic disorders and conditions, primarily associated with corneal weakness. The primary components of the Avedro Cross-Linking Platform are proprietary pharmaceutical formulations of riboflavin (vitamin B2), a “single dose pharmaceutical,” sold primarily in conjunction with the Company’s innovative devices for the delivery of metered doses of UVA light, a “medical device”. The technological advances that the Company has made with the Avedro Cross-Linking Platform have enabled the Company to expand the use of corneal cross-linking beyond the traditional areas in which it has been historically applied. In April 2016, the Company received United States Food and Drug Administration (“FDA”) clearance for the single dose pharmaceuticals Photrexa Viscous and Photrexa, and the KXL System medical device. The Company sells these products in the United States through a direct sales force and distributes its products outside of the United States through international medical device distributors. As of March 31, 2019, the Company has devoted the majority of its efforts to business planning, research and development, starting up production, developing markets, raising capital, recruiting management and technical staff and commercializing its newly approved products in the United States. Unaudited Interim Condensed Financial Statements The accompanying unaudited interim condensed financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”) for interim financial information and pursuant to Article 10 of Regulation S-X of the Securities Act of 1933, as amended (the “Securities Act”). Accordingly, they do not include all of the information and notes required by U.S. GAAP for complete financial statements. These unaudited interim condensed financial statements include only normal and recurring adjustments that the Company believes are necessary to fairly state the Company’s financial position and the results of operations and cash flows. Interim-period results are not necessarily indicative of results of operations or cash flows for a full year or any subsequent interim period. The condensed balance sheet at December 31, 2018 has been derived from audited financial statements at that date, but does not include all disclosures required by U.S. GAAP for complete financial statements. Because all of the disclosures required by U.S. GAAP for complete financial statements are not included herein, these unaudited interim condensed financial statements and the notes accompanying them should be read in conjunction with the audited financial statements and accompanying notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2018 as filed with the Securities and Exchange Commission on March 21, 2019. Reverse Stock Split On January 31, 2019, the Company’s board of directors and stockholders approved an amended and restated certificate of incorporation to, among other things, effect a reverse split on the outstanding shares of the Company’s common stock and convertible preferred stock on a one-for-4.45 basis (the “Reverse Stock Split”). The Reverse Stock Split became effective on February 1, 2019. The par values of the common stock and convertible preferred stock were not adjusted as a result of the Reverse Stock Split. Initial Public Offering In February 2019, the Company closed its initial public offering 10,635,89 202,981 Subsequent to the closing of the IPO, there were no shares of preferred stock or warrants to purchase shares of convertible preferred stock outstanding. Liquidity The Company has had recurring losses from operations since inception and has an accumulated deficit of $184,803 at March 31, 2019, and incurred net losses of $8,353 and $6,634 for the three months ended March 31, 2019 and 2018, respectively. Prior to the Company’s IPO, The Company had funded its operations principally from issuances of preferred stock, debt financings, and product and service sales. At March 31, 2019, the Company had $64,809 of unrestricted cash and cash equivalents. The Company expects the cash balance at March 31, 2019 will be sufficient to fund operations for a period of at least 12 months from the date the financial statements are issued. |
Summary of Significant Accounti
Summary of Significant Accounting Policies | 3 Months Ended |
Mar. 31, 2019 | |
Accounting Policies [Abstract] | |
Summary of Significant Accounting Policies | 2. Summary of Significant Accounting Policies Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that impact the reported amounts of assets, liabilities, revenues, and expenses and the disclosure of contingent assets and liabilities in the Company’s financial statements and accompanying notes. The most significant assumptions used in the financial statements are the underlying assumptions used in valuing share-based compensation including the fair value of the common stock, allowance for bad debts, the net realizable value of inventories, the valuation of variable transaction price in its contracts with customers, the determination of standalone selling price for contracts with customers, Fair Value Measurements The carrying amounts reported in the Company’s financial statements for cash and cash equivalents, accounts receivable, net of allowance, prepaid expenses and other current assets, accounts payable, accrued expenses and other current liabilities approximate their respective fair values because of the short-term nature of these accounts. The fair value of the Company’s long-term debt (see Note 7, “Long-Term Debt”) is determined using Level 3 inputs using current applicable rates for similar instruments as of the balance sheet dates and assessment of the credit rating of the Company. The carrying value of the Company’s long-term debt approximates fair value because the Company’s interest rate yield is near current market rates. The Company’s warrant liability, derivative liability and long-term debt are considered Level 3 liabilities within the fair value hierarchy described below. Fair value is defined as the price that would be received if selling an asset or paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Fair value measurements for assets and liabilities where there exists limited or no observable market data are based primarily upon estimates, and often are calculated based on the economic and competitive environment, the characteristics of the asset and liability and other factors. Therefore, the results cannot be determined with precision and may not be realized in an actual sale or immediate settlement of the asset or liability. Additionally, there may be inherent weaknesses in any valuation technique, and changes in the underlying assumptions used, including discount rates and estimates of future cash flows, that could significantly affect the results of current or future values. The Company’s financial assets are classified within the fair value hierarchy based on the lowest level of inputs that is significant to the fair value measurement. The three levels of the fair value hierarchy, and its applicability to the Company’s financial assets, are described as follows: Level 1 : Unadjusted quoted prices of identical, unrestricted assets in active markets that are accessible at the measurement date. Level 2 : Quoted prices for similar assets, or inputs that are observable, either directly or indirectly, for substantially the full term through corroboration with observable market data. Level 3 : Pricing inputs are unobservable for the assets, that is, inputs that reflect the Company’s own assumptions about the assumptions market participants would use in pricing the assets. There were no transfers between Levels 1, 2, and 3 during the three months ended March 31, 2019 and 2018. The Company has liabilities classified as Level 3 that are measured by management at fair value on a quarterly basis as described in Note 7, “Long-Term Debt,” and Note 9, “Warrants,” respectively. See Note 5, “Fair Value Measurements,” for additional information. Restricted Cash The Company has restricted cash of $551 at March 31, 2019 and December 31, 2018. $351 of the balance at March 31, 2019 and December 31, 2018 relates to two irrevocable standby letters of credit in relation to the Company’s office lease agreements. Each letter of credit names the lessor as the beneficiary and is required to fulfill lease requirements in the event the Company should default on office lease obligations. $200 of the balance at March 31, 2019 and December 31, 2018 is held to collateralize the Company’s credit card. Concentration of Credit Risk and Significant Customers Cash, cash equivalents and accounts receivable are financial instruments that potentially subject the Company to concentrations of credit risk. At March 31, 2019 and December 31, 2018, the Company invested its excess cash in money market funds through a United States bank with high credit ratings. The Company is exposed to credit risk in the event of a default by the financial institution holding its cash and cash equivalents to the extent recorded on the balance sheet. The Company has no financial instruments with off-balance sheet risk of loss. The Company has not experienced any significant losses in such accounts and management believes that the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which those deposits are held. The Company is also subject to credit risk from its accounts receivable. The Company sells its products through its direct sales organization in the United States and primarily through established distributors outside of the United States. To minimize credit risk, ongoing credit evaluations of customers’ financial condition are performed and upfront customer deposits are received prior to shipment whenever deemed necessary. The Company has not experienced any material losses related to receivables from individual customers, or groups of customers. During the three months ended March 31, 2019 and 2018, the Company did not recognize revenue from any single customer over 10% of total revenues. At December 31, 2018, the Company had one customer with an accounts receivable balance greater than 10% of total accounts receivable. No such customer existed at March 31, 2019. Convertible Preferred Stock The Company recorded its convertible preferred stock at fair value on the dates of issuance, net of issuance costs. A deemed liquidation event will only occur upon a greater than 50% change in control or a sale of substantially all of the assets of the Company and will be a redemption event subject to election by the holders of at least 70% of the then outstanding shares of convertible preferred stock, voting together as a single class on an as-converted basis. As the redemption event is outside the control of the Company, all shares of convertible preferred stock have been presented outside of permanent equity. As of December 31, 2018, it was not probable that such redemption would occur. Upon closing of the Company’s IPO on February 19, 2019, each share of convertible preferred stock automatically converted into shares of common stock at a conversion rate of one preferred share to one common share for each series of convertible preferred stock. Revenue Recognition The Company adopted ASC 606 on January 1, 2019 using the modified retrospective method for all contracts not completed as of the date of adoption. Under this method, the new guidance was applied to contracts that were not yet completed as of January 1, 2019 with the cumulative effect of initially applying the guidance recognized through accumulated deficit as the date of initial application. The reported results for 2019 reflect the application of ASC 606 guidance while the reported results for 2018 were prepared under the guidance of ASC 605, Revenue Recognition (“ASC 605”), which is also referred to herein as the "previous guidance.” The adoption of ASC 606 represents a change in accounting principle that will primarily impact how revenue is recognized for single dose pharmaceuticals sold in the United States and how the Company accounts for contract acquisition costs, such as commissions. See the “Financial Statement Impact of Adopting ASC 606” in Note 3 for further details. Revenue is recognized when, or as, obligations under the terms of a contract are satisfied, which occurs when control of the promised products or services is transferred to customers. Revenue is measured as the amount of consideration the Company expects to receive in exchange for transferring products or services to a customer (the “transaction price”). To the extent the transaction price includes variable consideration, the Company estimates the amount of variable consideration that should be included in the transaction price utilizing the expected value method or the most likely amount method, depending on the facts and circumstances relative to the contract. Variable consideration is included in the transaction price if, in the Company’s judgment, it is probable that a significant future reversal of cumulative revenue under the contract will not occur. Estimates of variable consideration and determination of whether to include estimated amounts in the transaction price are based largely on an assessment of the Company’s anticipated performance and all information (historical, current and forecasted) that is reasonably available. Sales, value add, and other taxes collected on behalf of third parties are excluded from revenue. When determining the transaction price of a contract, an adjustment is made if payment from a customer occurs either significantly before or significantly after performance, resulting in a significant financing component. The Company does not assess whether a significant financing component exists if the period between when the Company performs its obligations under the contract and when the customer pays is one year or less. None of the Company’s contracts contained a significant financing component as of January 1, 2019 or March 31, 2019. Contracts with customers may contain multiple performance obligations. For such arrangements, the transaction price is allocated to each performance obligation based on the estimated relative standalone selling prices of the promised products or services underlying each performance obligation. The Company determines standalone selling prices based on the price at which the performance obligation is sold separately. If the standalone selling price is not observable through past transactions, the Company estimates the standalone selling price taking into account available information such as market conditions and internally approved pricing guidelines related to the performance obligations. The Company has elected to account for the shipping and handling as an activity to fulfill the promise to transfer the product, and therefore will not evaluate whether shipping and handling activities are promised services to its customers. The Company recognizes product revenue under the terms of each customer agreement upon transfer of control to the customer, which occurs at a point in time. Service warranty revenue is recognized over the service warranty period, which is typically one to two years. The timing of revenue recognition, billings and cash collections results in accounts receivables and deferred revenue on the Company’s condensed U.S. Product Revenue Through its direct sales force, the Company sells medical devices and related single dose pharmaceuticals directly to customers, which are typically physicians, clinics or hospitals. A contract is deemed to exist on an initial device and related single dose pharmaceuticals sale when a sales agreement and order form for the device and single dose pharmaceuticals is executed. A contract for purchases of subsequent single dose pharmaceuticals exists when a reorder form is received and accepted by the Company. The performance obligations in the contracts for the delivery of these products may include medical devices, single dose pharmaceuticals, extended warranty service contracts and a customer option to purchase a single dose pharmaceutical in the future at a discount. The Company has, for a limited time, a program that offers a future discount on purchases subject to the customer meeting certain requirements, including one specifically related to the application for insurance reimbursement. The Company concluded the option to purchase a future dose at a discount is a material right and therefore constitutes a performance obligation. The Company provides a twelve (12) month warranty on medical devices sold in the United States and warrants to the customer that such devices will be free from defects in materials and workmanship under normal use and conditions. The Company also warrants that single dose pharmaceuticals will be free from defects in materials and workmanship, for one use, during the period up to, but not beyond, the sterility expiration for such product. These standard warranty provisions are assurance warranties accounted for as a cost accrual and not a separate performance obligation. The Company does not provide a right of return for any of its products; however, it may offer extended payment terms to its customers. For customers with extended payment terms, the Company determines if any of those amounts are variable and reduces the stated transaction price for the variable consideration. The Company allocates the transaction price to each performance obligation based on its relative standalone selling price. The stand-alone selling price of single dose pharmaceuticals and extended warranty service contracts is determined based on the price at which the Company typically sells the performance obligation separately, and the standalone selling price of medical devices is estimated based on a cost plus a reasonable profit margin. Revenue related to medical devices, single dose pharmaceuticals and the customers’ option to acquire additional single dose pharmaceuticals at a discount is generally recognized at a point in time upon transfer of control to the customer, which is generally . Revenue related to Outside the U.S. Product Revenue The Company has established distributor agreements with various distributors throughout the world to sell the Company’s medical devices, related single dose pharmaceuticals and spare parts. The term of the distributor agreements is typically two years, with each option of renewal not exceeding one year. A contract is deemed to exist with a distributor when a purchase order is received and accepted by the Company. The performance obligations in these contracts may include medical devices or single dose pharmaceuticals. The medical devices are generally covered by a warranty of 15 months following shipment or 12 months following installation at the end-customer site, and single dose pharmaceuticals are shipped with a minimum shelf life remaining until their sterility expiration, which is generally six to twelve months. These standard warranty provisions are assurance warranties accounted for as a cost accrual and not a separate performance obligation. The Company does not offer extended warranty service contracts to its distributors as all devices are serviced directly by the distributor. Distributors have no right of return or inventory swap-out provisions, and payments due under the contracts are not contingent upon the distributor’s sale of products to its customers and are invoiced upon shipment. The Company allocates the transaction price to each performance obligation based on its relative standalone selling price. The standalone selling price of medical devices, single dose pharmaceuticals and spare parts sold outside of the United States is determined based on the price at which the Company typically sells the performance obligation separately. Revenue related to medical devices and single dose pharmaceuticals is recognized at a point in time upon transfer of control to the customer, which is generally . Costs to Obtain or Fulfill a Customer Contract The Company’s sales commission structure is based on achieving revenue targets. Outside the United States, commissions are driven by revenue derived from customer purchase orders. In the United States, commissions are driven by revenue from device sales agreements in addition to revenue from single dose pharmaceuticals reorders. All commissions costs are costs to obtain a contract since they are incremental and would not have occurred absent a customer contract. Both the revenue derived from the single dose pharmaceuticals reorders and the revenue derived from purchase orders outside the United States are short term in nature. The renewal commissions are commensurate and therefore the amortization period is the contract duration; as such, the Company recognizes the incremental costs of obtaining these contracts as an expense when incurred. The Company capitalizes commission costs related to device sales in the United States. These costs are deferred in other assets on the Company's condensed balance sheet, net of the short-term portion included in prepaid expenses and other current assets. Costs to obtain these contracts are amortized as sales and marketing expense on a straight-line basis over the expected period of benefit and are also periodically reviewed for impairment. Product Warranty Internationally, medical devices sold are covered by a standard warranty for the shorter of 15 months following shipment or 12 months following installation. Medical devices sold within the United States are covered by a standard warranty for 12 months following installation. The Company records its estimated contractual obligations at the time of shipment since installations are generally within 30 days of shipment and returns are not accepted. The Company considers the 12-month rolling average of actual warranty claims associated with its medical devices and related single dose pharmaceuticals when determining the warranty accrual estimate. The estimates and assumptions used in developing the accrual estimate as of March 31, 2019 were consistent with prior periods. Changes in the product warranty accrual, included as part of accrued expenses, during the three months ended March 31, 2019 consisted of the following: Balance at December 31, 2018 $ 158 Accruals for warranties issued during the period (34 ) (Settlements) (2 ) Balance at March 31, 2019 $ 122 Share-Based Compensation The Company has a stock-based compensation plan which is more fully described in Note 10. The Company records stock-based compensation for share based awards granted to employees and to members of the board of directors for their services on the board of directors, based on the grant date fair value of awards issued, and the expense is recorded on a straight-line basis over the applicable service period, which is generally four years. For share based awards granted to employees with performance conditions, the Company utilizes the accelerated attribution method and does not recognize expense until the event is probable. The Company accounts for non-employee stock-based compensation arrangements based upon the fair value of the consideration received or the equity instruments issued, whichever is more reliably measurable. Prior to January 1, 2019, the measurement date for non-employee awards was generally the date that the performance of services required for the non-employee award is complete. Effective January 1, 2019, the Company adopted ASU 2018-07, “Improvements to Nonemployee Share-Based Payment Accounting” and now measures share-based payments to nonemployees at the grant date fair value. The Company expenses performance based options and restricted stock awards based on the fair value of the award on the date of issuance, on an accelerated attribution basis over the associated service period of the award once it is probable that the performance condition will be met. The Company uses the Black-Scholes option pricing model to determine the fair value of stock options. The use of the Black-Scholes option-pricing model requires management to make assumptions with respect to the expected term of the option, the expected volatility of the common stock consistent with the expected life of the option, risk-free interest rates and expected dividend yields of the common stock. The expected term was determined according to the simplified method, which is the average of the vesting tranche dates and the contractual term. Due to the lack of company specific historical and implied volatility data resulting from being a private company, the Company has based its estimate of expected volatility primarily on the historical volatility of a group of similar companies that are publicly traded. For these analyses, companies with comparable characteristics are selected, including enterprise value and position within the industry, and with historical share price information sufficient to meet the expected term of the stock-based awards. The Company computes the historical volatility data using the daily closing prices for the selected companies’ shares during the equivalent period of the calculated expected term of its stock-based awards. The risk-free interest rate is determined by reference to U.S. Treasury zero-coupon issues with remaining maturities similar to the expected term of the options. The Company has not paid, and does not anticipate paying, cash dividends on shares of preferred and common stock; therefore, the expected dividend yield is assumed to be zero. Prior to the Company’s IPO, the fair value of the underlying common stock was determined by the Company’s board of directors, with input from its management and the assistance of a third-party valuation specialist, by determining the equity value of the Company and then allocating this value among the different classes of equity securities based on their respective rights and individual characteristics. The equity value was determined using three different methods, which includes back-solving overall equity value to the price paid by recent financing transactions, using a combination of the market-based approach and the income approach, and also utilizing a hybrid method, as discussed below. For the valuation of the Company’s common stock on December 31, 2018, the Company accepted valuation method under the AICPA Practice Guide, for determining the fair value of the Company’s common stock. The PWERM is a scenario-based analysis that estimates the value per share of common stock based on the probability-weighted present value of expected future equity values for the common stock, under various possible future liquidity event scenarios, in light of the rights and preferences of each class and series of stock, discounted for a lack of marketability. Deferred Offering Costs Deferred offering costs consist of fees and expenses directly attributable to equity offerings. Upon completion of an offering, these amounts are offset against the proceeds of the offering. During 2018, the Company deferred offering costs related to its IPO totaling $2,829, which were capitalized and classified within noncurrent assets on the balance sheet as of December 31, 2018. Unpaid amounts as of December 31, 2018 totaled $1,601. U pon consummation of the Company’s IPO in February 2019, $4,075 of deferred offering costs were offset against the IPO proceeds and reclassified into equity. Net Loss Per Share Basic net loss per share attributable to common stockholders is computed by dividing the net loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding during the period, without consideration for potentially dilutive securities. Diluted net loss per share is computed by dividing the net loss attributable to common stockholders by the weighted-average number of shares of common stock and potentially dilutive securities outstanding during the period determined using the treasury-stock and if-converted methods. For purposes of the diluted net loss per share calculation, convertible preferred stock, stock options and warrants considered to be potentially dilutive securities, but were excluded from the calculation of diluted net loss per share because their effect would be anti-dilutive and therefore basic and diluted net loss per share were the same for all periods presented. Recent Accounting Pronouncements In May 2014, the FASB issued ASU No. 2014-09, “Revenue from Contracts with Customers (Topic 606),” (“ASC 606”) which supersedes the revenue recognition requirements in Accounting Standards Codification Topic 605, Revenue Recognition, and creates a new Topic 606, Revenue from Contracts with Customers. Two adoption methods are permitted: retrospectively to all prior reporting periods presented, with certain practical expedients permitted; or retrospectively with the cumulative effect of initially adopting the ASU recognized at the date of initial application. The adoption of this ASU included updates as provided under ASU 2015-14, “Revenue from Contracts with Customers (Topic 606): Deferral of the Effective Date”; ASU 2016-08, “Revenue from Contracts with Customers (Topic 606): Principal versus Agent Considerations (Reporting Revenue Gross versus Net)”; ASU 2016-10, “Revenue from Contracts with Customers (Topic 606): Identifying Performance Obligations and Licensing”; and ASU 2016-12, “Revenue from Contracts with Customers (Topic 606): Narrow-Scope Improvements and Practical Expedients.” The Company adopted the provisions of ASC 606 using the modified retrospective method effective January 1, 2019. See Notes 2 and 3 for further discussion of the effects of this standard on the Company’s financial statements. In June 2018, the FASB issued ASU 2018-07, “Improvements to Nonemployee Share-Based Payment Accounting.” The new standard simplifies the accounting for share-based payments to nonemployees by aligning it with the accounting for share-based payments to employees, with certain exceptions. The Company adopted this standard as of January 1, 2019, and the adoption of this standard did not have a material impact on the Company’s financial statements. In November 2016, the FASB issued ASU 2016-18, “Statement of Cash Flows: Restricted Cash”. The amendments in this update require that amounts generally described as restricted cash and restricted cash equivalents be included within cash and cash equivalents when reconciling the beginning-of-period and end-of-period total amounts shown on the statement of cash flows. The Company adopted this standard on a retrospective basis on January 1, 2018. The adoption resulted in an increase to cash, cash equivalents and restricted cash of $551 in the statement of cash flows at March 31, 2019 and 2018. In February 2016, the FASB issued ASU 2016-02, “Leases (Topic 842)”, which requires an entity to recognize assets and liabilities arising from a lease for both financing and operating leases. The ASU will also require new qualitative and quantitative disclosures to help investors and other financial statement users better understand the amount, timing, and uncertainty of cash flows arising from leases. ASU 2016-02 is effective for fiscal years beginning after December 15, 2019, with early adoption permitted. The Company is currently evaluating the effect ASU 2016-02 will have on its financial statements. |
Revenue Recognition
Revenue Recognition | 3 Months Ended |
Mar. 31, 2019 | |
Revenues [Abstract] | |
Revenue Recognition | 3. Revenue Recognition Disaggregation of Revenue When disaggregating revenue, the Company considered all of the economic factors that may affect its revenues. Because all of its revenues are from ophthalmologists and other eye care professionals, there are no differences in the nature, timing and uncertainty of the Company’s revenues and cash flows from any of its product lines. However, given that the Company’s revenues are generated in different geographic regions, factors such as regulatory and geopolitical factors within those regions could impact the nature, timing and uncertainty of the Company’s revenues and cash flows. The following tables disaggregate the Company’s revenue from contracts with customers by geographic region: Three Months Ended March 31, 2019 2018 Amount Amount United States $ 6,511 $ 3,194 Asia 860 890 Europe 737 623 Americas (outside the United States) 225 142 Middle East 338 194 Other 102 111 Total revenues $ 8,773 $ 5,154 Contract Balances from Contracts with Customers The following table provides information about receivables and deferred revenue from contracts with customers as of March 31, 2019: As of March 31, 2019 Balances from contracts with customers only: Accounts receivable $ 10,973 Deferred revenue 800 Three Months Ended March 31, 2019 Revenue recognized in the period relating to: The beginning deferred revenue balance $ 407 Changes in pricing related to products or services satisfied in previous periods — Impairment losses on receivables — Transaction Price Allocated to Future Performance Obligations The Company’s future performance obligations primarily relate to customers’ right to a future discount single dose pharmaceutical purchases in the United States, and, to a lesser extent, . At right to a future discount Costs to Obtain or Fulfill a Customer Contract As of March 31, 2019, capitalized contract acquisition costs were $254, including a current balance of $160 and a non-current balance of $94. The Company recognized $49 of amortization of capitalized commission costs during the three months ended March 31, 2019. There were no impairments to capitalized costs to obtain a contract recorded during the period. Financial Statement Impact of Adopting ASC 606 The cumulative effect of applying the new guidance to all contracts with customers that were not completed as of January 1, 2019 was recorded as an adjustment to accumulated deficit as of the adoption date. The following table shows the adjustments made to accounts on the condensed balance sheet as of January 1, 2019 as a result of adopting the new guidance. The table also compares the reported condensed balance sheet accounts as of March 31, 2019 that were impacted by the new guidance to pro forma balance sheet amounts had the previous guidance been in effect. As Reported Adjustments (2) As Adjusted As Adjustments Pro forma (4) 12/31/2018 1/1/2019 1/1/2019 3/31/2019 3/31/2019 3/31/2019 Assets Accounts receivable (a) $ 4,725 $ 5,481 $ 10,206 $ 10,973 $ (2,694 ) $ 8,279 Prepaid expenses and other current assets (b) 1,919 178 2,097 3,116 (160 ) 2,956 Total current assets 20,672 5,659 26,331 83,371 (2,854 ) 80,517 Other assets (b) 291 125 416 380 (94 ) 286 Total Assets $ 25,867 $ 5,784 $ 31,651 $ 85,749 $ (2,948 ) $ 82,801 Liabilities and Stockholders' Equity (Deficit) Accrued expenses and other current liabilities 5,366 — 5,366 5,134 20 5,154 Deferred revenue (c) 688 112 800 779 (107 ) 672 Total current liabilities 8,430 112 8,542 8,684 (87 ) 8,597 Accumulated deficit (182,122 ) 5,672 (176,450 ) (184,803 ) (2,861 ) (187,664 ) Total stockholders' equity (deficit) (73,588 ) 5,672 (67,916 ) 56,272 (2,861 ) 53,411 Total Liabilities and Stockholders' Equity (Deficit) $ 25,867 $ 5,784 $ 31,651 $ 85,749 $ (2,948 ) $ 82,801 (1) Financial statement amounts as reported in the Company's balance sheet as of December 31, 2018. Financial statement amounts that are not shown on the above table were not impacted by the adoption of ASC 606. (2) Adjustments made on January 1, 2019 to adopt ASC 606. (3) Financial statement amounts as reported in the interim condensed balance sheet as of March 31, 2019. Financial statement amounts that are not shown on the above table were not impacted by the adoption of the adoption of ASC 606. (4) Pro forma balance sheet amounts that would have been reported as of March 31, 2019 had the Company applied the previous guidance under ASC 605. (a) Single dose pharmaceutical amounts invoiced to customers under extended payment terms are included in the Company’s balance sheet for the amount that represents the transaction price consideration they will receive. (b) Other current and non-current assets include contract acquisition costs related to the sale of devices in the United States. These costs are amortized over the estimated period of benefit. (c) The Company recorded deferred revenue for a customers’ right to a future discount The following summarizes the significant changes on the Company’s condensed statement of operations for the three months ended March 31, 2019 as a result of the adoption of ASC 606 on January 1, 2019 compared to if the Company had continued to recognize revenue under ASC 605: Three Months Ended March 31, 2019 As reported Adjustments Pro forma as if the previous accounting guidance was in effect Revenue (a) $ 8,773 $ 2,783 $ 11,556 Gross profit 6,489 2,783 9,272 Selling, general and administrative (b) 10,221 (28 ) 10,193 Total operating expenses 14,506 (28 ) 14,478 Loss from operations (8,017 ) 2,811 (5,206 ) Net loss $ (8,353 ) $ 2,811 $ (5,542 ) Net loss per share of common stock, basic and diluted $ (1.00 ) $ 0.34 $ (0.66 ) (a) Single dose pharmaceutical revenue in the United States under ASC 606 includes the recognition of amounts invoiced under extended payment terms upon shipment if the Company does not believe it is probable that a significant reversal of revenue would occur upon settlement of the receivable (b) ASC 606 resulted in the amortization of capitalized commission costs that were recorded as part of the cumulative effect adjustment upon adoption. Amortization of these capitalized costs to selling, general and administrative expenses, net of commission costs that were capitalized in the quarter, increased selling, general and administrative expenses in the quarter. The following summarizes the significant changes on the Company’s condensed statement of cash flow for the three months ended March 31, 2019 as a result of the adoption of ASC 606 on January 1, 2019 compared to if the Company had continued to recognize revenue under ASC 605: Three Months Ended March 31, 2019 Statement of Cash Flows As reported Adjustments Pro forma as if the previous accounting guidance was in effect Net loss $ (8,353 ) $ 2,811 $ (5,542 ) Adjustments to reconcile net loss to net cash used in operating activities: Accounts receivable (752 ) (2,787 ) (3,539 ) Prepaid expenses and other current assets (1,019 ) (18 ) (1,037 ) Accounts payable and accrued expenses 341 20 361 Deferred revenue (12 ) 5 (7 ) Other non-current assets and liabilities 48 (31 ) 17 Net cash used in operating activities $ (8,547 ) $ — $ (8,547 ) The adoption of ASC 606 had no net impact on the Company’s cash used in operating, investing or financing activities. |
Condensed Balance Sheet Compone
Condensed Balance Sheet Components | 3 Months Ended |
Mar. 31, 2019 | |
Balance Sheet Related Disclosures [Abstract] | |
Condensed Balance Sheet Components | 4. Condensed Balance Sheet Components Inventories, net Inventories consisted of the following: As of March 31, As of December 31, 2019 2018 Raw materials $ 2,534 $ 2,688 Finished goods 1,939 1,571 Total inventories $ 4,473 $ 4,259 Prepaid Expenses and Other Current Assets Prepaid expenses and other current assets consisted of the following: As of March 31, As of December 31, 2019 2018 Prepaid suppliers $ 449 $ 503 Prepaid rent 112 107 Prepaid insurance 994 65 Prepaid prescription drug user fee 310 465 Prepaid license fees 321 226 Prepaid clinical studies 174 154 Prepaid other expenses 756 399 Total prepaid expenses and other current assets $ 3,116 $ 1,919 Equipment and Furniture, Net Equipment and furniture, net consisted of the following: As of March 31, As of December 31, 2019 2018 Machinery and lab equipment $ 1,529 $ 1,478 Medical devices used for internal purposes 939 929 Computer software 238 215 Office furniture and equipment 424 423 Computer hardware 373 361 Total equipment and furniture 3,503 3,406 Less: accumulated depreciation (2,056 ) (1,882 ) Equipment and furniture, net $ 1,447 $ 1,524 Depreciation expense for the three months ended March 31, 2019 and 2018 was $174 and $169, respectively. Accrued Expenses Accrued expenses and other current liabilities consisted of the following: As of March 31, As of December 31, 2019 2018 Accrued compensation $ 1,870 $ 2,836 Accrued warranty 122 158 Accrued inventory 115 33 Accrued professional services 1,760 1,421 Accrued reimbursement hub costs 731 264 Accrued sales tax 65 75 Accrued other 471 579 Total accrued expenses and other current liabilities $ 5,134 $ 5,366 |
Fair Value Measurements
Fair Value Measurements | 3 Months Ended |
Mar. 31, 2019 | |
Fair Value Disclosures [Abstract] | |
Fair Value Measurements | 5. Fair Value Measurements The carrying amount reflected on the balance sheets for cash and cash equivalents, accounts receivable, prepaid expenses and other current assets, accounts payable and accrued liabilities approximated their fair values, due to the short-term nature of these instruments. The carrying value of the long-term debt approximates its fair value as the debt arrangement is based on interest rates the Company believes it could obtain for borrowings with similar terms. Recurring Fair Value Measurements The following tables set forth the Company’s assets and liabilities that were accounted for at fair value on a recurring basis as of March 31, 2019 and December 31, 2018: Description Total Quoted prices in active markets (Level 1) Significant other observable inputs (Level 2) Significant unobservable inputs (Level 3) March 31, 2019 Assets Cash equivalents $ 63,342 $ 63,342 $ — $ — $ 63,342 $ 63,342 $ — $ — Liabilities Derivative liability $ 197 — — 197 $ 197 $ — $ — $ 197 December 31, 2018 Assets Cash equivalents $ 8,164 $ 8,164 $ — $ — $ 8,164 $ 8,164 $ — $ — Liabilities Warrant liability $ 1,800 $ — $ — $ 1,800 Derivative liability $ 406 — — 406 $ 2,206 $ — $ — $ 2,206 Cash Equivalents Cash equivalents consist of money market funds with an original maturity of three months or less from the date of purchase. Cash equivalents are carried at cost, which approximates their fair value. At March 31, 2019 and December 31, 2018, the Company held $63,342 and $8,164 of cash equivalents, respectively, all of which were invested in money market funds. Warrant Liability The warrant liability represents the liability for warrants to purchase shares of Series AA convertible preferred stock issued in connection with the Company’s long-term debt (see Note 9, “Warrants”). The fair value of the Series AA convertible preferred stock warrants was determined using the Black-Scholes model, a form of an option pricing model. The weighted-average assumptions used in the Black-Scholes option pricing model to determine the fair value of the warrants were as follows: Three Months Ended March 31, 2019 2018 Risk-free interest rate 2.5% - 2.6% 2.6% - 2.7% Expected volatility 60.2% - 61.4% 58.0% - 61.3% Expected term (in years) 5.6 - 8.1 6.5 - 9.0 Expected dividend yield 0.0 % 0.0 % Risk-free Interest Rate. The Company estimated the risk-free interest rate in reference to yield on U.S. Treasury securities with a maturity date commensurate with the expected term of the associated warrant. Expected Volatility. Due to the Company’s limited operating history and lack of company-specific historical or implied volatility, the expected volatility assumption is based on historical volatilities of a peer group of similar companies whose share prices are publicly available over a period commensurate with the warrant’s expected term. The peer group was developed based on companies in the biotechnology and medical device industries. Expected Term. The expected term represents the period of time that warrants are expected to be outstanding. Expected Dividend Yield. The expected dividend yield assumption is based on the fact that the Company has never paid cash dividends and has no present intention to pay cash dividends. Fair Value of Underlying Convertible Preferred Shares. The fair value of the underlying convertible preferred stock was determined by the board of directors, with input from management and the assistance of a third-party valuation specialist, by determining the equity value of the Company and then allocating this value among the different classes of equity securities based on their respective rights and individual characteristics. The equity value was determined using three different methods, which includes back-solving overall equity value to the price paid by recent financing transactions, a probability-weighted expected return method, and also using a combination of the market-based approach and the income approach. The fair value of the Company’s equity value was then allocated to various securities within the Company’s capital structure by applying an option pricing method. The option pricing method estimates the fair value of each class of security based on the potential to profit from the upside of the business, while taking into account the unique characteristics of each class of security. For the valuation of our common stock on December 31, 2018, the Company utilized the probability-weighted expected return method, or PWERM, in combination with the option pricing method, or OPM, as a hybrid method, or Hybrid Method, which is an accepted valuation method under the AICPA Practice Guide, for determining the fair value of our common stock. The PWERM is a scenario-based analysis that estimates the value per share of common stock based on the probability-weighted present value of expected future equity values for the common stock, under various possible future liquidity event scenarios, in light of the rights and preferences of each class and series of stock, discounted for a lack of marketability. The OPM values each equity class by creating a series of call options on the equity value, with exercise prices based on the liquidation preferences, participation rights and strike prices of derivatives. The Hybrid Method is appropriate for a company expecting a near term liquidity event, but where, due to market or other factors, the likelihood of completing the liquidity event is uncertain. The Hybrid Method considers a company’s going concern nature, stage of development and ability to forecast near and long-term future liquidity scenarios. Upon closing of the Company’s IPO, the Company utilized the close price of their common stock to value the warrant liability on the date they were converted in shares to purchase common stock and reclassified into equity. Accordingly, the valuation of the components of the warrant liability was determined using Level 3 inputs. Changes in the fair value of the warrant liability, for which fair value is determined using Level 3 inputs were as follows: Balance at December 31, 2018 $ 1,800 Change in fair value of warrant liability 35 Reclassification of a warrant liability to equity (1,835 ) Balance at March 31, 2019 $ — Derivative Liability The derivative liability represents features bifurcated from the 2017 Credit Agreement liability and recorded at fair value. See Note 7, “Long-Term Debt.” Under certain change in control events, as defined in the 2017 Credit Agreement, a prepayment fee and the entire outstanding obligation may be due and payable. The Company concluded that these features, including (i) interest rate upon a non-creditworthy event of default; (ii) a put option upon an event of default; and (iii) a put option upon the lenders request of net casualty proceeds, are not clearly and closely related to the host instrument, and represent a single compound derivative and is required to be re-measured at fair value. The estimated fair value of the derivative liability was determined using a probability-weighted discounted cash flow model that includes the principal, prepayment fees and interest payments under scenarios of a change in control, other than a qualified initial public offering prior to the debt maturity. The following inputs were estimated by management: (i) the probability of a change of control event; (ii) the timing of a change of control event; and (iii) the discount rate. At March 31, 2019, the Company assumed a 17% discount rate, and a 5% and 10% probability for a change in control event during the twelve months ended March 19, 2020 and 2021, respectively. Changes in the fair value of the derivative liability, for which fair value is determined using Level 3 inputs were as follows: Balance at December 31, 2018 $ 406 Change in fair value (209 ) Balance at March 31, 2019 $ 197 |
Commitments and Contingencies
Commitments and Contingencies | 3 Months Ended |
Mar. 31, 2019 | |
Commitments And Contingencies Disclosure [Abstract] | |
Commitments and Contingencies | 6. Commitments and Contingencies In the ordinary course of business, the Company may be subject to legal proceedings, claims and litigation as the Company operates in an industry susceptible to patent legal claims. The Company accounts for estimated losses with respect to legal proceedings and claims when such losses are probable and estimable. Legal costs associated with these matters are expensed when incurred. The Company is not currently a party to any legal proceedings. |
Long-term Debt
Long-term Debt | 3 Months Ended |
Mar. 31, 2019 | |
Debt Disclosure [Abstract] | |
Long-term Debt | 7. Long-Term Debt Long-term debt, net, is comprised of the following: As of March 31, As of December 31, 2019 2018 Principal amount outstanding $ 20,000 $ 20,000 PIK Interest 801 657 Unamortized discount (464 ) (495 ) Unamortized issue costs (209 ) (223 ) Net carrying amount $ 20,128 $ 19,939 As of March 31, 2019 and December 31, 2018, the Company had borrowed and had outstanding $20,000 of debt under the 2017 Credit Agreement, maturing on March 20, 2022 (the “Maturity Date”). The 2017 Credit Agreement requires payment of interest only until maturity at the rate of 10% per annum (the “Applicable Margin”). Additional interest (“PIK”) accrues at the per annum rate equal to the higher of (i) the three-month LIBOR rate and (ii) 1.00%. Such PIK interest is added to the outstanding principal amount of the loans until the maturity date. The outstanding loan balance plus accrued PIK interest is due in one lump sum payment on the Maturity Date. The Company’s obligations under the 2017 Credit Agreement are secured by a security interest in substantially all of its assets. Other than a minimum liquidity requirement of $3,000, there are no financial covenants contained in the 2017 Credit Agreement and the Company is in compliance with the affirmative and restrictive covenants as of March 31, 2019 . |
Capitalization
Capitalization | 3 Months Ended |
Mar. 31, 2019 | |
Equity [Abstract] | |
Capitalization | 8. Capitalization On February 19, 2019, upon the closing of the IPO, all outstanding shares of convertible preferred stock were automatically converted into 10,635,894 shares of common stock. Also upon the closing of the IPO, the Company filed an amended and restated certificate of incorporation (the “Restated Certificate”) authorizing the Company to issue is a total of 210,000,000 shares, with 200,000,000 share designated as common stock and 10,000,000 shares designated as preferred stock, each having a par value of $0.00001. The Company has reserved for future issuance the following number of shares of common stock on a fully diluted and as-converted basis: As of March 31, As of December 31, 2019 2018 Conversion of Series AA convertible preferred stock — 7,161,719 Conversion of Series BB convertible preferred stock — 1,332,708 Conversion of Series CC convertible preferred stock — 2,141,467 Options to purchase common stock 3,126,728 2,490,767 Vesting of restricted stock units to common stock 17,630 18,522 Employee stock purchase plan 350,000 — Remaining shares available for issuance 2,592,095 104,828 Warrants to purchase convertible preferred stock — 174,032 Warrants to purchase common stock 200,820 28,949 Total 6,287,273 13,452,992 |
Warrants
Warrants | 3 Months Ended |
Mar. 31, 2019 | |
Warrants And Rights Note Disclosure [Abstract] | |
Warrants | 9. Warrants Upon the closing of the Company’s IPO, all of the outstanding warrants to purchase shares of convertible preferred stock were automatically converted into warrants to purchase shares of common stock. The following represents a summary of the warrants outstanding at each of the dates identified: Outstanding at Issued Classification Exercisable for March 31, 2019 1 2015 Equity Common stock 26,788 2 2015 Equity Common stock 67,415 3 2017 Equity Common stock 106,617 Outstanding at Issued Classification Exercisable for December 31, 2018 1 2015 Equity Common stock 28,949 2 2015 Liability Series AA convertible preferred stock 67,415 3 2017 Liability Series AA convertible preferred stock 106,617 1 Exercisable through November 5, 2021 at $0.05 per share. 2 Exercisable through September 11, 2024, at $4.45 per share. 3 Exercisable through March 20, 2027, at $4.45 per share. |
Share-Based Compensation
Share-Based Compensation | 3 Months Ended |
Mar. 31, 2019 | |
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract] | |
Share-Based Compensation | 10. Share-Based Compensation 2019 Equity Incentive Plan In January 2019, the Company’s board of directors adopted, and the Company’s stockholders approved, the 2019 Equity Incentive Plan (the “2019 Plan”). The 2019 Plan became effective on the effective date of the IPO, at which time the Company ceased making awards under the 2012 Plan. Under the 2019 Plan, the Company may grant stock options qualifying as incentive stock options (“ISOs”) within the meaning of Section 422 of U.S. Internal Revenue Code of 1986, as amended, or the Code, to employees, and for the grant of nonstatutory stock options (“NSOs”) restricted stock awards, restricted stock unit awards, stock appreciation rights, performance stock awards and other forms of stock compensation to employees, consultants and directors. The 2019 Plan also provides for the grant of performance cash awards to employees, consultants and directors. A total of 2,500,000 shares of common stock were initially reserved for issuance under the 2019 Plan. In addition, the number of shares available for issuance under the 2019 Plan will automatically increase on January 1 of each year, for a period of ten years, from January 1, 2020 continuing through January 1, 2029, by 4% of the total number of shares of common stock outstanding on December 31 of the preceding calendar year, or a lesser number of shares as may be determined by the Company’s board of directors. The maximum number of shares that may be issued pursuant to the exercise of ISOs under the 2019 Plan is 2,500,000. 2019 Employee Stock Purchase Plan In January 2019, the Company’s board of directors adopted, and the Company’s stockholders approved, the 2019 Employee Stock Purchase Plan (the “2019 ESPP”). The 2019 ESPP became effective on the effective date of the IPO. The maximum number of shares of common stock that may be issued under the ESPP is 350,000 shares. Additionally, the number of shares of common stock reserved for issuance will automatically increase on January 1 of each calendar year, from January 1, 2020 through January 1, 2029, by the lesser of (1) 1% of the total number of shares of common stock outstanding on December 31 of the preceding calendar year and (2) 500,000 shares; provided, that prior to the date of any such increase, the Company’s board of directors may determine that such increase will be less than the amount set forth in clauses (1) and (2). The 2019 ESPP will become active upon approval of the plan administrator, which is the Company’s board of directors. Stock Option Activity Stock option activity under the 2019 Plan is summarized as follows: Number of Options Average Exercise Price Remaining Contractual Term (in years) Aggregate Intrinsic Value Outstanding at December 31, 2018 2,490,767 $ 2.83 8.7 $ 25,111 Granted 664,598 $ 12.69 Exercised (2,985 ) $ 2.61 Forfeited/cancelled (25,652 ) $ 2.69 Outstanding at March 31, 2019 3,126,728 $ 4.92 8.8 $ 1,335 Vested and expected to vest at March 31, 2019 3,126,728 $ 4.92 8.8 $ 1,335 Exercisable at March 31, 2019 1,234,741 $ 2.83 8.1 $ 1,011 Unrecognized compensation expense related to outstanding options was $6,086 at March 31, 2019, which is expected to be recognized as expense over approximately 2.3 years. The following table summarizes information relating to stock options granted and exercised: Three Months Ended March 31, 2019 2018 Weighted-average grant date fair value per share of option grants $ 7.37 $ 1.22 Aggregate intrinsic value of options exercised 4 31 The aggregate intrinsic value represents the difference between the fair value at exercise and the exercise price paid by the employee. Restricted Stock Units In January 2018, the Company granted restricted stock units covering a total of 18,522 shares of common stock to certain executives. These restricted stock units have both a liquidity event and service-based vesting term. The liquidity event requirement was met in February 2019 upon the consummation of our IPO. The service-based requirement vests 50% of the grant on February 1, 2018, with the reminder vesting in eight quarterly equal installments over a two-year period for each quarter of continuous service thereafter. The Company has recorded $36,675 of stock-based compensation expense for these restricted stock units during the three months ended March 31, 2019. No such expense was recorded during the three months ended March 31, 2018 as the liquidity event requirement was not yet satisfied. In March 2019, the Company granted restricted stock units covering a total of 13,000 shares of common stock to a certain executive. Th ese restricted stock units Unrecognized compensation expense relating to restricted stock units was $174 at March 31, 2019, which is expected to be recognized as expense over approximately 3.9 years. Share-Based Compensation Expense The following table presents stock-based compensation expense included in the Company’s statements of operations for the three months ended March 31, 2019 and 2018: Three Months Ended March 31, 2019 2018 Cost of goods sold $ 33 $ 13 Selling, general and administrative 1,010 337 Research and development 207 56 $ 1,250 $ 406 Valuation of Stock Options The weighted-average assumptions used in the Black-Scholes option pricing model to determine the fair value of all stock options granted in the period were as follows: Three Months Ended March 31, 2019 2018 Risk-free interest rate 2.6 % 2.5 % Expected volatility 61.3 % 58.0 % Expected term (in years) 6.0 5.6 Expected dividend yield 0.0 % 0.0 % Risk-free Interest Rate. The Company estimated the risk-free interest rate in reference to yield on U.S. Treasury securities with a maturity date commensurate with the expected term of the associated award. Expected Volatility. Due to the Company’s limited operating history and lack of company-specific historical or implied volatility, the expected volatility assumption is based on historical volatilities of a peer group of similar companies whose share prices are publicly available over a period commensurate with the option’s expected term. The peer group was developed based on companies in the biotechnology and medical device industries. Expected Term. The expected term represents the period of time that options are expected to be outstanding. Because the Company does not have historical exercise behavior, through March 31, 2019, it determined the expected life assumption for employees using the simplified method, which is an average of the contractual term of the option and its vesting period. For non-employees, the Company determined the expected life to be the contractual term of the option. Expected Dividend Yield. The expected dividend yield assumption is based on the fact that the Company has never paid cash dividends and has no present intention to pay cash dividends. |
Net Loss Per Share
Net Loss Per Share | 3 Months Ended |
Mar. 31, 2019 | |
Earnings Per Share [Abstract] | |
Net Loss Per Share | 11. Net Loss Per Share The following potentially dilutive securities outstanding have been excluded from the computations of diluted weighted average shares outstanding because such securities have an antidilutive impact due to losses reported: As of March 31, As of December 31, 2019 2018 Series AA convertible preferred stock — 7,161,719 Series BB convertible preferred stock — 1,332,708 Series CC convertible preferred stock — 2,141,467 Outstanding stock options 3,126,728 2,490,767 Unvested restricted stock units 17,630 18,522 Outstanding Series AA convertible preferred stock warrants — 174,032 Outstanding common stock warrants 200,820 28,949 Total 3,345,178 13,348,164 |
Related Party Transactions
Related Party Transactions | 3 Months Ended |
Mar. 31, 2019 | |
Related Party Transactions [Abstract] | |
Related Party Transactions | 12. Related Party Transactions The Company has a customer that is also a stockholder. During the three months ended March 31, 2019, and 2018, the Company recorded revenue related to this customer of $469 and $498, respectively. The accounts receivable balance from this customer as of March 31, 2019 and December 31, 2018 was $469 and $561, respectively. The Company has a customer that is also a stockholder and employee. During the three months ended March 31, 2019, and 2018, the Company recorded revenue related to this customer of $111 and $14, respectively. The accounts receivable balance from this customer as of March 31, 2019 and December 31, 2018 was $176 and $12, respectively. The Company also entered into a lending arrangement in March 2017 with a lender who is affiliated with a stockholder. See Note 7, “Long-term Debt” for further details. |
Summary of Significant Accoun_2
Summary of Significant Accounting Policies (Policies) | 3 Months Ended |
Mar. 31, 2019 | |
Accounting Policies [Abstract] | |
Use Of Estimates | Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that impact the reported amounts of assets, liabilities, revenues, and expenses and the disclosure of contingent assets and liabilities in the Company’s financial statements and accompanying notes. The most significant assumptions used in the financial statements are the underlying assumptions used in valuing share-based compensation including the fair value of the common stock, allowance for bad debts, the net realizable value of inventories, the valuation of variable transaction price in its contracts with customers, the determination of standalone selling price for contracts with customers, |
Fair Value Measurements | Fair Value Measurements The carrying amounts reported in the Company’s financial statements for cash and cash equivalents, accounts receivable, net of allowance, prepaid expenses and other current assets, accounts payable, accrued expenses and other current liabilities approximate their respective fair values because of the short-term nature of these accounts. The fair value of the Company’s long-term debt (see Note 7, “Long-Term Debt”) is determined using Level 3 inputs using current applicable rates for similar instruments as of the balance sheet dates and assessment of the credit rating of the Company. The carrying value of the Company’s long-term debt approximates fair value because the Company’s interest rate yield is near current market rates. The Company’s warrant liability, derivative liability and long-term debt are considered Level 3 liabilities within the fair value hierarchy described below. Fair value is defined as the price that would be received if selling an asset or paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Fair value measurements for assets and liabilities where there exists limited or no observable market data are based primarily upon estimates, and often are calculated based on the economic and competitive environment, the characteristics of the asset and liability and other factors. Therefore, the results cannot be determined with precision and may not be realized in an actual sale or immediate settlement of the asset or liability. Additionally, there may be inherent weaknesses in any valuation technique, and changes in the underlying assumptions used, including discount rates and estimates of future cash flows, that could significantly affect the results of current or future values. The Company’s financial assets are classified within the fair value hierarchy based on the lowest level of inputs that is significant to the fair value measurement. The three levels of the fair value hierarchy, and its applicability to the Company’s financial assets, are described as follows: Level 1 : Unadjusted quoted prices of identical, unrestricted assets in active markets that are accessible at the measurement date. Level 2 : Quoted prices for similar assets, or inputs that are observable, either directly or indirectly, for substantially the full term through corroboration with observable market data. Level 3 : Pricing inputs are unobservable for the assets, that is, inputs that reflect the Company’s own assumptions about the assumptions market participants would use in pricing the assets. There were no transfers between Levels 1, 2, and 3 during the three months ended March 31, 2019 and 2018. The Company has liabilities classified as Level 3 that are measured by management at fair value on a quarterly basis as described in Note 7, “Long-Term Debt,” and Note 9, “Warrants,” respectively. See Note 5, “Fair Value Measurements,” for additional information. |
Restricted Cash | Restricted Cash The Company has restricted cash of $551 at March 31, 2019 and December 31, 2018. $351 of the balance at March 31, 2019 and December 31, 2018 relates to two irrevocable standby letters of credit in relation to the Company’s office lease agreements. Each letter of credit names the lessor as the beneficiary and is required to fulfill lease requirements in the event the Company should default on office lease obligations. $200 of the balance at March 31, 2019 and December 31, 2018 is held to collateralize the Company’s credit card. |
Concentration of Credit Risk and Significant Customers | Concentration of Credit Risk and Significant Customers Cash, cash equivalents and accounts receivable are financial instruments that potentially subject the Company to concentrations of credit risk. At March 31, 2019 and December 31, 2018, the Company invested its excess cash in money market funds through a United States bank with high credit ratings. The Company is exposed to credit risk in the event of a default by the financial institution holding its cash and cash equivalents to the extent recorded on the balance sheet. The Company has no financial instruments with off-balance sheet risk of loss. The Company has not experienced any significant losses in such accounts and management believes that the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which those deposits are held. The Company is also subject to credit risk from its accounts receivable. The Company sells its products through its direct sales organization in the United States and primarily through established distributors outside of the United States. To minimize credit risk, ongoing credit evaluations of customers’ financial condition are performed and upfront customer deposits are received prior to shipment whenever deemed necessary. The Company has not experienced any material losses related to receivables from individual customers, or groups of customers. During the three months ended March 31, 2019 and 2018, the Company did not recognize revenue from any single customer over 10% of total revenues. At December 31, 2018, the Company had one customer with an accounts receivable balance greater than 10% of total accounts receivable. No such customer existed at March 31, 2019. |
Convertible Preferred Stock | Convertible Preferred Stock The Company recorded its convertible preferred stock at fair value on the dates of issuance, net of issuance costs. A deemed liquidation event will only occur upon a greater than 50% change in control or a sale of substantially all of the assets of the Company and will be a redemption event subject to election by the holders of at least 70% of the then outstanding shares of convertible preferred stock, voting together as a single class on an as-converted basis. As the redemption event is outside the control of the Company, all shares of convertible preferred stock have been presented outside of permanent equity. As of December 31, 2018, it was not probable that such redemption would occur. Upon closing of the Company’s IPO on February 19, 2019, each share of convertible preferred stock automatically converted into shares of common stock at a conversion rate of one preferred share to one common share for each series of convertible preferred stock. |
Revenue Recognition | Revenue Recognition The Company adopted ASC 606 on January 1, 2019 using the modified retrospective method for all contracts not completed as of the date of adoption. Under this method, the new guidance was applied to contracts that were not yet completed as of January 1, 2019 with the cumulative effect of initially applying the guidance recognized through accumulated deficit as the date of initial application. The reported results for 2019 reflect the application of ASC 606 guidance while the reported results for 2018 were prepared under the guidance of ASC 605, Revenue Recognition (“ASC 605”), which is also referred to herein as the "previous guidance.” The adoption of ASC 606 represents a change in accounting principle that will primarily impact how revenue is recognized for single dose pharmaceuticals sold in the United States and how the Company accounts for contract acquisition costs, such as commissions. See the “Financial Statement Impact of Adopting ASC 606” in Note 3 for further details. Revenue is recognized when, or as, obligations under the terms of a contract are satisfied, which occurs when control of the promised products or services is transferred to customers. Revenue is measured as the amount of consideration the Company expects to receive in exchange for transferring products or services to a customer (the “transaction price”). To the extent the transaction price includes variable consideration, the Company estimates the amount of variable consideration that should be included in the transaction price utilizing the expected value method or the most likely amount method, depending on the facts and circumstances relative to the contract. Variable consideration is included in the transaction price if, in the Company’s judgment, it is probable that a significant future reversal of cumulative revenue under the contract will not occur. Estimates of variable consideration and determination of whether to include estimated amounts in the transaction price are based largely on an assessment of the Company’s anticipated performance and all information (historical, current and forecasted) that is reasonably available. Sales, value add, and other taxes collected on behalf of third parties are excluded from revenue. When determining the transaction price of a contract, an adjustment is made if payment from a customer occurs either significantly before or significantly after performance, resulting in a significant financing component. The Company does not assess whether a significant financing component exists if the period between when the Company performs its obligations under the contract and when the customer pays is one year or less. None of the Company’s contracts contained a significant financing component as of January 1, 2019 or March 31, 2019. Contracts with customers may contain multiple performance obligations. For such arrangements, the transaction price is allocated to each performance obligation based on the estimated relative standalone selling prices of the promised products or services underlying each performance obligation. The Company determines standalone selling prices based on the price at which the performance obligation is sold separately. If the standalone selling price is not observable through past transactions, the Company estimates the standalone selling price taking into account available information such as market conditions and internally approved pricing guidelines related to the performance obligations. The Company has elected to account for the shipping and handling as an activity to fulfill the promise to transfer the product, and therefore will not evaluate whether shipping and handling activities are promised services to its customers. The Company recognizes product revenue under the terms of each customer agreement upon transfer of control to the customer, which occurs at a point in time. Service warranty revenue is recognized over the service warranty period, which is typically one to two years. The timing of revenue recognition, billings and cash collections results in accounts receivables and deferred revenue on the Company’s condensed U.S. Product Revenue Through its direct sales force, the Company sells medical devices and related single dose pharmaceuticals directly to customers, which are typically physicians, clinics or hospitals. A contract is deemed to exist on an initial device and related single dose pharmaceuticals sale when a sales agreement and order form for the device and single dose pharmaceuticals is executed. A contract for purchases of subsequent single dose pharmaceuticals exists when a reorder form is received and accepted by the Company. The performance obligations in the contracts for the delivery of these products may include medical devices, single dose pharmaceuticals, extended warranty service contracts and a customer option to purchase a single dose pharmaceutical in the future at a discount. The Company has, for a limited time, a program that offers a future discount on purchases subject to the customer meeting certain requirements, including one specifically related to the application for insurance reimbursement. The Company concluded the option to purchase a future dose at a discount is a material right and therefore constitutes a performance obligation. The Company provides a twelve (12) month warranty on medical devices sold in the United States and warrants to the customer that such devices will be free from defects in materials and workmanship under normal use and conditions. The Company also warrants that single dose pharmaceuticals will be free from defects in materials and workmanship, for one use, during the period up to, but not beyond, the sterility expiration for such product. These standard warranty provisions are assurance warranties accounted for as a cost accrual and not a separate performance obligation. The Company does not provide a right of return for any of its products; however, it may offer extended payment terms to its customers. For customers with extended payment terms, the Company determines if any of those amounts are variable and reduces the stated transaction price for the variable consideration. The Company allocates the transaction price to each performance obligation based on its relative standalone selling price. The stand-alone selling price of single dose pharmaceuticals and extended warranty service contracts is determined based on the price at which the Company typically sells the performance obligation separately, and the standalone selling price of medical devices is estimated based on a cost plus a reasonable profit margin. Revenue related to medical devices, single dose pharmaceuticals and the customers’ option to acquire additional single dose pharmaceuticals at a discount is generally recognized at a point in time upon transfer of control to the customer, which is generally . Revenue related to Outside the U.S. Product Revenue The Company has established distributor agreements with various distributors throughout the world to sell the Company’s medical devices, related single dose pharmaceuticals and spare parts. The term of the distributor agreements is typically two years, with each option of renewal not exceeding one year. A contract is deemed to exist with a distributor when a purchase order is received and accepted by the Company. The performance obligations in these contracts may include medical devices or single dose pharmaceuticals. The medical devices are generally covered by a warranty of 15 months following shipment or 12 months following installation at the end-customer site, and single dose pharmaceuticals are shipped with a minimum shelf life remaining until their sterility expiration, which is generally six to twelve months. These standard warranty provisions are assurance warranties accounted for as a cost accrual and not a separate performance obligation. The Company does not offer extended warranty service contracts to its distributors as all devices are serviced directly by the distributor. Distributors have no right of return or inventory swap-out provisions, and payments due under the contracts are not contingent upon the distributor’s sale of products to its customers and are invoiced upon shipment. The Company allocates the transaction price to each performance obligation based on its relative standalone selling price. The standalone selling price of medical devices, single dose pharmaceuticals and spare parts sold outside of the United States is determined based on the price at which the Company typically sells the performance obligation separately. Revenue related to medical devices and single dose pharmaceuticals is recognized at a point in time upon transfer of control to the customer, which is generally . Costs to Obtain or Fulfill a Customer Contract The Company’s sales commission structure is based on achieving revenue targets. Outside the United States, commissions are driven by revenue derived from customer purchase orders. In the United States, commissions are driven by revenue from device sales agreements in addition to revenue from single dose pharmaceuticals reorders. All commissions costs are costs to obtain a contract since they are incremental and would not have occurred absent a customer contract. Both the revenue derived from the single dose pharmaceuticals reorders and the revenue derived from purchase orders outside the United States are short term in nature. The renewal commissions are commensurate and therefore the amortization period is the contract duration; as such, the Company recognizes the incremental costs of obtaining these contracts as an expense when incurred. The Company capitalizes commission costs related to device sales in the United States. These costs are deferred in other assets on the Company's condensed balance sheet, net of the short-term portion included in prepaid expenses and other current assets. Costs to obtain these contracts are amortized as sales and marketing expense on a straight-line basis over the expected period of benefit and are also periodically reviewed for impairment. Product Warranty Internationally, medical devices sold are covered by a standard warranty for the shorter of 15 months following shipment or 12 months following installation. Medical devices sold within the United States are covered by a standard warranty for 12 months following installation. The Company records its estimated contractual obligations at the time of shipment since installations are generally within 30 days of shipment and returns are not accepted. The Company considers the 12-month rolling average of actual warranty claims associated with its medical devices and related single dose pharmaceuticals when determining the warranty accrual estimate. The estimates and assumptions used in developing the accrual estimate as of March 31, 2019 were consistent with prior periods. Changes in the product warranty accrual, included as part of accrued expenses, during the three months ended March 31, 2019 consisted of the following: Balance at December 31, 2018 $ 158 Accruals for warranties issued during the period (34 ) (Settlements) (2 ) Balance at March 31, 2019 $ 122 |
Share-Based Compensation | Share-Based Compensation The Company has a stock-based compensation plan which is more fully described in Note 10. The Company records stock-based compensation for share based awards granted to employees and to members of the board of directors for their services on the board of directors, based on the grant date fair value of awards issued, and the expense is recorded on a straight-line basis over the applicable service period, which is generally four years. For share based awards granted to employees with performance conditions, the Company utilizes the accelerated attribution method and does not recognize expense until the event is probable. The Company accounts for non-employee stock-based compensation arrangements based upon the fair value of the consideration received or the equity instruments issued, whichever is more reliably measurable. Prior to January 1, 2019, the measurement date for non-employee awards was generally the date that the performance of services required for the non-employee award is complete. Effective January 1, 2019, the Company adopted ASU 2018-07, “Improvements to Nonemployee Share-Based Payment Accounting” and now measures share-based payments to nonemployees at the grant date fair value. The Company expenses performance based options and restricted stock awards based on the fair value of the award on the date of issuance, on an accelerated attribution basis over the associated service period of the award once it is probable that the performance condition will be met. The Company uses the Black-Scholes option pricing model to determine the fair value of stock options. The use of the Black-Scholes option-pricing model requires management to make assumptions with respect to the expected term of the option, the expected volatility of the common stock consistent with the expected life of the option, risk-free interest rates and expected dividend yields of the common stock. The expected term was determined according to the simplified method, which is the average of the vesting tranche dates and the contractual term. Due to the lack of company specific historical and implied volatility data resulting from being a private company, the Company has based its estimate of expected volatility primarily on the historical volatility of a group of similar companies that are publicly traded. For these analyses, companies with comparable characteristics are selected, including enterprise value and position within the industry, and with historical share price information sufficient to meet the expected term of the stock-based awards. The Company computes the historical volatility data using the daily closing prices for the selected companies’ shares during the equivalent period of the calculated expected term of its stock-based awards. The risk-free interest rate is determined by reference to U.S. Treasury zero-coupon issues with remaining maturities similar to the expected term of the options. The Company has not paid, and does not anticipate paying, cash dividends on shares of preferred and common stock; therefore, the expected dividend yield is assumed to be zero. Prior to the Company’s IPO, the fair value of the underlying common stock was determined by the Company’s board of directors, with input from its management and the assistance of a third-party valuation specialist, by determining the equity value of the Company and then allocating this value among the different classes of equity securities based on their respective rights and individual characteristics. The equity value was determined using three different methods, which includes back-solving overall equity value to the price paid by recent financing transactions, using a combination of the market-based approach and the income approach, and also utilizing a hybrid method, as discussed below. For the valuation of the Company’s common stock on December 31, 2018, the Company accepted valuation method under the AICPA Practice Guide, for determining the fair value of the Company’s common stock. The PWERM is a scenario-based analysis that estimates the value per share of common stock based on the probability-weighted present value of expected future equity values for the common stock, under various possible future liquidity event scenarios, in light of the rights and preferences of each class and series of stock, discounted for a lack of marketability. |
Deferred Offering Costs | Deferred Offering Costs Deferred offering costs consist of fees and expenses directly attributable to equity offerings. Upon completion of an offering, these amounts are offset against the proceeds of the offering. During 2018, the Company deferred offering costs related to its IPO totaling $2,829, which were capitalized and classified within noncurrent assets on the balance sheet as of December 31, 2018. Unpaid amounts as of December 31, 2018 totaled $1,601. U pon consummation of the Company’s IPO in February 2019, $4,075 of deferred offering costs were offset against the IPO proceeds and reclassified into equity. |
Net Loss Per Share | Net Loss Per Share Basic net loss per share attributable to common stockholders is computed by dividing the net loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding during the period, without consideration for potentially dilutive securities. Diluted net loss per share is computed by dividing the net loss attributable to common stockholders by the weighted-average number of shares of common stock and potentially dilutive securities outstanding during the period determined using the treasury-stock and if-converted methods. For purposes of the diluted net loss per share calculation, convertible preferred stock, stock options and warrants considered to be potentially dilutive securities, but were excluded from the calculation of diluted net loss per share because their effect would be anti-dilutive and therefore basic and diluted net loss per share were the same for all periods presented. |
Recent Accounting Pronouncements | Recent Accounting Pronouncements In May 2014, the FASB issued ASU No. 2014-09, “Revenue from Contracts with Customers (Topic 606),” (“ASC 606”) which supersedes the revenue recognition requirements in Accounting Standards Codification Topic 605, Revenue Recognition, and creates a new Topic 606, Revenue from Contracts with Customers. Two adoption methods are permitted: retrospectively to all prior reporting periods presented, with certain practical expedients permitted; or retrospectively with the cumulative effect of initially adopting the ASU recognized at the date of initial application. The adoption of this ASU included updates as provided under ASU 2015-14, “Revenue from Contracts with Customers (Topic 606): Deferral of the Effective Date”; ASU 2016-08, “Revenue from Contracts with Customers (Topic 606): Principal versus Agent Considerations (Reporting Revenue Gross versus Net)”; ASU 2016-10, “Revenue from Contracts with Customers (Topic 606): Identifying Performance Obligations and Licensing”; and ASU 2016-12, “Revenue from Contracts with Customers (Topic 606): Narrow-Scope Improvements and Practical Expedients.” The Company adopted the provisions of ASC 606 using the modified retrospective method effective January 1, 2019. See Notes 2 and 3 for further discussion of the effects of this standard on the Company’s financial statements. In June 2018, the FASB issued ASU 2018-07, “Improvements to Nonemployee Share-Based Payment Accounting.” The new standard simplifies the accounting for share-based payments to nonemployees by aligning it with the accounting for share-based payments to employees, with certain exceptions. The Company adopted this standard as of January 1, 2019, and the adoption of this standard did not have a material impact on the Company’s financial statements. In November 2016, the FASB issued ASU 2016-18, “Statement of Cash Flows: Restricted Cash”. The amendments in this update require that amounts generally described as restricted cash and restricted cash equivalents be included within cash and cash equivalents when reconciling the beginning-of-period and end-of-period total amounts shown on the statement of cash flows. The Company adopted this standard on a retrospective basis on January 1, 2018. The adoption resulted in an increase to cash, cash equivalents and restricted cash of $551 in the statement of cash flows at March 31, 2019 and 2018. In February 2016, the FASB issued ASU 2016-02, “Leases (Topic 842)”, which requires an entity to recognize assets and liabilities arising from a lease for both financing and operating leases. The ASU will also require new qualitative and quantitative disclosures to help investors and other financial statement users better understand the amount, timing, and uncertainty of cash flows arising from leases. ASU 2016-02 is effective for fiscal years beginning after December 15, 2019, with early adoption permitted. The Company is currently evaluating the effect ASU 2016-02 will have on its financial statements. |
Summary of Significant Accoun_3
Summary of Significant Accounting Policies (Tables) | 3 Months Ended |
Mar. 31, 2019 | |
Accounting Policies [Abstract] | |
Changes in Product Warranty Accrual, Included Accrued Expenses | Changes in the product warranty accrual, included as part of accrued expenses, during the three months ended March 31, 2019 consisted of the following: Balance at December 31, 2018 $ 158 Accruals for warranties issued during the period (34 ) (Settlements) (2 ) Balance at March 31, 2019 $ 122 |
Revenue Recognition (Tables)
Revenue Recognition (Tables) | 3 Months Ended |
Mar. 31, 2019 | |
Revenues [Abstract] | |
Summary of Disaggregate of Revenue from Contracts with Customers by Geographic Region | The following tables disaggregate the Company’s revenue from contracts with customers by geographic region: Three Months Ended March 31, 2019 2018 Amount Amount United States $ 6,511 $ 3,194 Asia 860 890 Europe 737 623 Americas (outside the United States) 225 142 Middle East 338 194 Other 102 111 Total revenues $ 8,773 $ 5,154 |
Summary of Receivables and Deferred Revenue from Contracts with Customers | The following table provides information about receivables and deferred revenue from contracts with customers as of March 31, 2019: As of March 31, 2019 Balances from contracts with customers only: Accounts receivable $ 10,973 Deferred revenue 800 Three Months Ended March 31, 2019 Revenue recognized in the period relating to: The beginning deferred revenue balance $ 407 Changes in pricing related to products or services satisfied in previous periods — Impairment losses on receivables — |
Summary of Adjustment to Accounts on the Condensed Balance Sheet | The cumulative effect of applying the new guidance to all contracts with customers that were not completed as of January 1, 2019 was recorded as an adjustment to accumulated deficit as of the adoption date. The following table shows the adjustments made to accounts on the condensed balance sheet as of January 1, 2019 as a result of adopting the new guidance. The table also compares the reported condensed balance sheet accounts as of March 31, 2019 that were impacted by the new guidance to pro forma balance sheet amounts had the previous guidance been in effect. As Reported Adjustments (2) As Adjusted As Adjustments Pro forma (4) 12/31/2018 1/1/2019 1/1/2019 3/31/2019 3/31/2019 3/31/2019 Assets Accounts receivable (a) $ 4,725 $ 5,481 $ 10,206 $ 10,973 $ (2,694 ) $ 8,279 Prepaid expenses and other current assets (b) 1,919 178 2,097 3,116 (160 ) 2,956 Total current assets 20,672 5,659 26,331 83,371 (2,854 ) 80,517 Other assets (b) 291 125 416 380 (94 ) 286 Total Assets $ 25,867 $ 5,784 $ 31,651 $ 85,749 $ (2,948 ) $ 82,801 Liabilities and Stockholders' Equity (Deficit) Accrued expenses and other current liabilities 5,366 — 5,366 5,134 20 5,154 Deferred revenue (c) 688 112 800 779 (107 ) 672 Total current liabilities 8,430 112 8,542 8,684 (87 ) 8,597 Accumulated deficit (182,122 ) 5,672 (176,450 ) (184,803 ) (2,861 ) (187,664 ) Total stockholders' equity (deficit) (73,588 ) 5,672 (67,916 ) 56,272 (2,861 ) 53,411 Total Liabilities and Stockholders' Equity (Deficit) $ 25,867 $ 5,784 $ 31,651 $ 85,749 $ (2,948 ) $ 82,801 (1) Financial statement amounts as reported in the Company's balance sheet as of December 31, 2018. Financial statement amounts that are not shown on the above table were not impacted by the adoption of ASC 606. (2) Adjustments made on January 1, 2019 to adopt ASC 606. (3) Financial statement amounts as reported in the interim condensed balance sheet as of March 31, 2019. Financial statement amounts that are not shown on the above table were not impacted by the adoption of the adoption of ASC 606. (4) Pro forma balance sheet amounts that would have been reported as of March 31, 2019 had the Company applied the previous guidance under ASC 605. (a) Single dose pharmaceutical amounts invoiced to customers under extended payment terms are included in the Company’s balance sheet for the amount that represents the transaction price consideration they will receive. (b) Other current and non-current assets include contract acquisition costs related to the sale of devices in the United States. These costs are amortized over the estimated period of benefit. (c) The Company recorded deferred revenue for a customers’ right to a future discount |
Summary of Significant Changes on Condensed Statement of Operations | The following summarizes the significant changes on the Company’s condensed statement of operations for the three months ended March 31, 2019 as a result of the adoption of ASC 606 on January 1, 2019 compared to if the Company had continued to recognize revenue under ASC 605: Three Months Ended March 31, 2019 As reported Adjustments Pro forma as if the previous accounting guidance was in effect Revenue (a) $ 8,773 $ 2,783 $ 11,556 Gross profit 6,489 2,783 9,272 Selling, general and administrative (b) 10,221 (28 ) 10,193 Total operating expenses 14,506 (28 ) 14,478 Loss from operations (8,017 ) 2,811 (5,206 ) Net loss $ (8,353 ) $ 2,811 $ (5,542 ) Net loss per share of common stock, basic and diluted $ (1.00 ) $ 0.34 $ (0.66 ) (a) Single dose pharmaceutical revenue in the United States under ASC 606 includes the recognition of amounts invoiced under extended payment terms upon shipment if the Company does not believe it is probable that a significant reversal of revenue would occur upon settlement of the receivable (b) ASC 606 resulted in the amortization of capitalized commission costs that were recorded as part of the cumulative effect adjustment upon adoption. Amortization of these capitalized costs to selling, general and administrative expenses, net of commission costs that were capitalized in the quarter, increased selling, general and administrative expenses in the quarter. |
Summary of Significant Changes on Condensed Statement of Cash Flow | The following summarizes the significant changes on the Company’s condensed statement of cash flow for the three months ended March 31, 2019 as a result of the adoption of ASC 606 on January 1, 2019 compared to if the Company had continued to recognize revenue under ASC 605: Three Months Ended March 31, 2019 Statement of Cash Flows As reported Adjustments Pro forma as if the previous accounting guidance was in effect Net loss $ (8,353 ) $ 2,811 $ (5,542 ) Adjustments to reconcile net loss to net cash used in operating activities: Accounts receivable (752 ) (2,787 ) (3,539 ) Prepaid expenses and other current assets (1,019 ) (18 ) (1,037 ) Accounts payable and accrued expenses 341 20 361 Deferred revenue (12 ) 5 (7 ) Other non-current assets and liabilities 48 (31 ) 17 Net cash used in operating activities $ (8,547 ) $ — $ (8,547 ) |
Condensed Balance Sheet Compo_2
Condensed Balance Sheet Components (Tables) | 3 Months Ended |
Mar. 31, 2019 | |
Balance Sheet Related Disclosures [Abstract] | |
Schedule of Inventories | Inventories consisted of the following: As of March 31, As of December 31, 2019 2018 Raw materials $ 2,534 $ 2,688 Finished goods 1,939 1,571 Total inventories $ 4,473 $ 4,259 |
Schedule of Prepaid Expenses and Other Current Assets | Prepaid expenses and other current assets consisted of the following: As of March 31, As of December 31, 2019 2018 Prepaid suppliers $ 449 $ 503 Prepaid rent 112 107 Prepaid insurance 994 65 Prepaid prescription drug user fee 310 465 Prepaid license fees 321 226 Prepaid clinical studies 174 154 Prepaid other expenses 756 399 Total prepaid expenses and other current assets $ 3,116 $ 1,919 |
Components of Equipment and Furniture, Net | Equipment and furniture, net consisted of the following: As of March 31, As of December 31, 2019 2018 Machinery and lab equipment $ 1,529 $ 1,478 Medical devices used for internal purposes 939 929 Computer software 238 215 Office furniture and equipment 424 423 Computer hardware 373 361 Total equipment and furniture 3,503 3,406 Less: accumulated depreciation (2,056 ) (1,882 ) Equipment and furniture, net $ 1,447 $ 1,524 |
Components of Accrued Expenses and Other Current Liabilities | Accrued expenses and other current liabilities consisted of the following: As of March 31, As of December 31, 2019 2018 Accrued compensation $ 1,870 $ 2,836 Accrued warranty 122 158 Accrued inventory 115 33 Accrued professional services 1,760 1,421 Accrued reimbursement hub costs 731 264 Accrued sales tax 65 75 Accrued other 471 579 Total accrued expenses and other current liabilities $ 5,134 $ 5,366 |
Fair Value Measurements (Tables
Fair Value Measurements (Tables) | 3 Months Ended |
Mar. 31, 2019 | |
Schedule of Assets and Liabilities Measured at Fair Value on Recurring Basis | The following tables set forth the Company’s assets and liabilities that were accounted for at fair value on a recurring basis as of March 31, 2019 and December 31, 2018: Description Total Quoted prices in active markets (Level 1) Significant other observable inputs (Level 2) Significant unobservable inputs (Level 3) March 31, 2019 Assets Cash equivalents $ 63,342 $ 63,342 $ — $ — $ 63,342 $ 63,342 $ — $ — Liabilities Derivative liability $ 197 — — 197 $ 197 $ — $ — $ 197 December 31, 2018 Assets Cash equivalents $ 8,164 $ 8,164 $ — $ — $ 8,164 $ 8,164 $ — $ — Liabilities Warrant liability $ 1,800 $ — $ — $ 1,800 Derivative liability $ 406 — — 406 $ 2,206 $ — $ — $ 2,206 |
Derivative Liability | |
Schedule of Change in the Fair Value of Liability | Changes in the fair value of the derivative liability, for which fair value is determined using Level 3 inputs were as follows: Balance at December 31, 2018 $ 406 Change in fair value (209 ) Balance at March 31, 2019 $ 197 |
Warrant Liability | |
Schedule of Weighted-Average Assumptions Used to Determine Fair Value | The weighted-average assumptions used in the Black-Scholes option pricing model to determine the fair value of the warrants were as follows: Three Months Ended March 31, 2019 2018 Risk-free interest rate 2.5% - 2.6% 2.6% - 2.7% Expected volatility 60.2% - 61.4% 58.0% - 61.3% Expected term (in years) 5.6 - 8.1 6.5 - 9.0 Expected dividend yield 0.0 % 0.0 % |
Schedule of Change in the Fair Value of Liability | Changes in the fair value of the warrant liability, for which fair value is determined using Level 3 inputs were as follows: Balance at December 31, 2018 $ 1,800 Change in fair value of warrant liability 35 Reclassification of a warrant liability to equity (1,835 ) Balance at March 31, 2019 $ — |
Long-term Debt (Tables)
Long-term Debt (Tables) | 3 Months Ended |
Mar. 31, 2019 | |
Debt Disclosure [Abstract] | |
Summary of Long-Term Debt, Net | Long-term debt, net, is comprised of the following: As of March 31, As of December 31, 2019 2018 Principal amount outstanding $ 20,000 $ 20,000 PIK Interest 801 657 Unamortized discount (464 ) (495 ) Unamortized issue costs (209 ) (223 ) Net carrying amount $ 20,128 $ 19,939 |
Capitalization (Tables)
Capitalization (Tables) | 3 Months Ended |
Mar. 31, 2019 | |
Equity [Abstract] | |
Summary of Shares of Common Stock Reserved for Future Issuance | The Company has reserved for future issuance the following number of shares of common stock on a fully diluted and as-converted basis: As of March 31, As of December 31, 2019 2018 Conversion of Series AA convertible preferred stock — 7,161,719 Conversion of Series BB convertible preferred stock — 1,332,708 Conversion of Series CC convertible preferred stock — 2,141,467 Options to purchase common stock 3,126,728 2,490,767 Vesting of restricted stock units to common stock 17,630 18,522 Employee stock purchase plan 350,000 — Remaining shares available for issuance 2,592,095 104,828 Warrants to purchase convertible preferred stock — 174,032 Warrants to purchase common stock 200,820 28,949 Total 6,287,273 13,452,992 |
Warrants (Tables)
Warrants (Tables) | 3 Months Ended |
Mar. 31, 2019 | |
Warrants And Rights Note Disclosure [Abstract] | |
Summary of the Warrants Outstanding | The following represents a summary of the warrants outstanding at each of the dates identified: Outstanding at Issued Classification Exercisable for March 31, 2019 1 2015 Equity Common stock 26,788 2 2015 Equity Common stock 67,415 3 2017 Equity Common stock 106,617 Outstanding at Issued Classification Exercisable for December 31, 2018 1 2015 Equity Common stock 28,949 2 2015 Liability Series AA convertible preferred stock 67,415 3 2017 Liability Series AA convertible preferred stock 106,617 |
Share-Based Compensation (Table
Share-Based Compensation (Tables) | 3 Months Ended |
Mar. 31, 2019 | |
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract] | |
Schedule of Stock Option Activity | Stock option activity under the 2019 Plan is summarized as follows: Number of Options Average Exercise Price Remaining Contractual Term (in years) Aggregate Intrinsic Value Outstanding at December 31, 2018 2,490,767 $ 2.83 8.7 $ 25,111 Granted 664,598 $ 12.69 Exercised (2,985 ) $ 2.61 Forfeited/cancelled (25,652 ) $ 2.69 Outstanding at March 31, 2019 3,126,728 $ 4.92 8.8 $ 1,335 Vested and expected to vest at March 31, 2019 3,126,728 $ 4.92 8.8 $ 1,335 Exercisable at March 31, 2019 1,234,741 $ 2.83 8.1 $ 1,011 |
Summary of Stock Options Granted and Exercised | The following table summarizes information relating to stock options granted and exercised: Three Months Ended March 31, 2019 2018 Weighted-average grant date fair value per share of option grants $ 7.37 $ 1.22 Aggregate intrinsic value of options exercised 4 31 |
Schedule of Stock-based Compensation Expense | The following table presents stock-based compensation expense included in the Company’s statements of operations for the three months ended March 31, 2019 and 2018: Three Months Ended March 31, 2019 2018 Cost of goods sold $ 33 $ 13 Selling, general and administrative 1,010 337 Research and development 207 56 $ 1,250 $ 406 |
Schedule of Weighted Average Assumptions Used to Determine Fair Value of Stock Option Granted | The weighted-average assumptions used in the Black-Scholes option pricing model to determine the fair value of all stock options granted in the period were as follows: Three Months Ended March 31, 2019 2018 Risk-free interest rate 2.6 % 2.5 % Expected volatility 61.3 % 58.0 % Expected term (in years) 6.0 5.6 Expected dividend yield 0.0 % 0.0 % |
Net Loss Per Share (Tables)
Net Loss Per Share (Tables) | 3 Months Ended |
Mar. 31, 2019 | |
Earnings Per Share [Abstract] | |
Schedule of Dilutive Securities Outstanding Excluded from Diluted Weighted Average Share Outstanding | The following potentially dilutive securities outstanding have been excluded from the computations of diluted weighted average shares outstanding because such securities have an antidilutive impact due to losses reported: As of March 31, As of December 31, 2019 2018 Series AA convertible preferred stock — 7,161,719 Series BB convertible preferred stock — 1,332,708 Series CC convertible preferred stock — 2,141,467 Outstanding stock options 3,126,728 2,490,767 Unvested restricted stock units 17,630 18,522 Outstanding Series AA convertible preferred stock warrants — 174,032 Outstanding common stock warrants 200,820 28,949 Total 3,345,178 13,348,164 |
Nature of Business and Basis _2
Nature of Business and Basis of Presentation - Additional Information (Details) | Feb. 19, 2019shares | Jan. 31, 2019 | Feb. 28, 2019USD ($)$ / sharesshares | Mar. 31, 2019USD ($)shares | Mar. 31, 2018USD ($) | Dec. 31, 2018USD ($) |
Nature of Business and Basis of Presentation [Line Items] | ||||||
Reverse stock split | one-for-4.45 basis | |||||
Reverse stock split, conversion ratio | 0.225 | |||||
Outstanding preferred stock or warrants to purchase shares of convertible preferred stock | $ | $ 0 | |||||
Accumulated deficit | $ | $ (184,803,000) | |||||
Net losses | $ | 8,353,000 | $ 6,634,000 | ||||
Unrestricted cash and cash equivalents | $ | $ 64,809,000 | $ 9,769,000 | ||||
Common Stock | ||||||
Nature of Business and Basis of Presentation [Line Items] | ||||||
Common stock issued and sold | 5,000,000 | |||||
Convertible preferred stock converted into common stock | 10,635,894 | |||||
IPO | ||||||
Nature of Business and Basis of Presentation [Line Items] | ||||||
Common stock issued and sold | 10,635,894 | |||||
Net proceeds from stock issued and sold | $ | $ 61,025,000 | |||||
Warrants to purchase common stock upon conversion | 202,981 | |||||
IPO | Common Stock | ||||||
Nature of Business and Basis of Presentation [Line Items] | ||||||
Common stock issued and sold | 5,000,000 | |||||
Pubic offering price per share | $ / shares | $ 14 | |||||
Convertible preferred stock converted into common stock | 10,635,894 |
Summary of Significant Accoun_4
Summary of Significant Accounting Policies - Additional Information (Details) $ in Thousands | 3 Months Ended | 12 Months Ended | ||
Mar. 31, 2019USD ($)LetterCustomer | Mar. 31, 2018USD ($) | Dec. 31, 2018USD ($)LetterCustomer | Feb. 19, 2019USD ($) | |
Summary Of Significant Accounting Policies [Line Items] | ||||
Restricted cash | $ 551 | $ 551 | ||
Number of irrevocable standby letters of credit | Letter | 2 | 2 | ||
Restricted cash held to collateral | $ 200 | $ 200 | ||
Concentration risk, customer | During the three months ended March 31, 2019 and 2018, the Company did not recognize revenue from any single customer over 10% of total revenues. At December 31, 2018, the Company had one customer with an accounts receivable balance greater than 10% of total accounts receivable. No such customer existed at March 31, 2019. | |||
Convertible preferred stock threshold percentage of outstanding shares | 70.00% | |||
Convertible preferred stock, conversion basis | one preferred share to one common share | |||
Share based awards granted to employees, term | 4 years | |||
Expected dividend yield | 0.00% | |||
Deferred offering costs | 2,829 | |||
Unpaid deferred offering costs | 1,601 | |||
Increase to cash, cash equivalents and restricted cash | $ 55,040 | $ (5,183) | ||
ASU 2016-02 | ||||
Summary Of Significant Accounting Policies [Line Items] | ||||
Increase to cash, cash equivalents and restricted cash | $ 551 | $ 551 | ||
IPO | ||||
Summary Of Significant Accounting Policies [Line Items] | ||||
Deferred offering costs | $ 2,829 | $ 4,075 | ||
Geographic Distribution, Foreign | Outside U.S | ||||
Summary Of Significant Accounting Policies [Line Items] | ||||
Right of return, inventory swap-out provisions description | Distributors have no right of return or inventory swap-out provisions | |||
Term of distributor agreements | 2 years | |||
Maximum renewal term of distributor agreements | 1 year | |||
Estimate contractual obligations shipment installations returns period | 30 days | |||
Geographic Distribution, Foreign | Outside U.S | Medical Devices | ||||
Summary Of Significant Accounting Policies [Line Items] | ||||
Product warranty, following shipment | 15 months | |||
Product warranty, following installation | 12 months | |||
Geographic Distribution, Foreign | Outside U.S | Single Dose Pharmaceuticals | ||||
Summary Of Significant Accounting Policies [Line Items] | ||||
Minimum shelf life, sterility expiration period | 12 months | |||
Geographic Distribution, Foreign | United States | Medical Devices | ||||
Summary Of Significant Accounting Policies [Line Items] | ||||
Product warranty, following installation | 12 months | |||
Minimum | ||||
Summary Of Significant Accounting Policies [Line Items] | ||||
Deemed liquidation event sale of assets percentage | 50.00% | |||
Service warranty period | 1 year | |||
Minimum | Geographic Distribution, Foreign | Outside U.S | Single Dose Pharmaceuticals | ||||
Summary Of Significant Accounting Policies [Line Items] | ||||
Minimum shelf life, sterility expiration period | 6 months | |||
Maximum | ||||
Summary Of Significant Accounting Policies [Line Items] | ||||
Service warranty period | 2 years | |||
Maximum | Geographic Distribution, Foreign | Outside U.S | Single Dose Pharmaceuticals | ||||
Summary Of Significant Accounting Policies [Line Items] | ||||
Minimum shelf life, sterility expiration period | 12 months | |||
Customer Concentration Risk | Accounts Receivable | ||||
Summary Of Significant Accounting Policies [Line Items] | ||||
Number of customer with more than 10% accounts receivable balance | Customer | 0 | 1 | ||
Customer Concentration Risk | Accounts Receivable | Minimum | ||||
Summary Of Significant Accounting Policies [Line Items] | ||||
Concentration risk percentage | 10.00% | 10.00% | ||
Standby Letters of Credit | ||||
Summary Of Significant Accounting Policies [Line Items] | ||||
Restricted cash | $ 351 | $ 351 |
Summary of Significant Accoun_5
Summary of Significant Accounting Policies - Changes in Product Warranty Accrual Included Accrued Expenses (Details) $ in Thousands | 3 Months Ended |
Mar. 31, 2019USD ($) | |
Accounting Policies [Abstract] | |
Balance at December 31, 2018 | $ 158 |
Accruals for warranties issued during the period | (34) |
(Settlements) | (2) |
Balance at March 31, 2019 | $ 122 |
Revenue Recognition - Summary o
Revenue Recognition - Summary of Disaggregate of Revenue from Contracts with Customers by Geographic Region (Details) - USD ($) $ in Thousands | 3 Months Ended | |
Mar. 31, 2019 | Mar. 31, 2018 | |
Disaggregation Of Revenue [Line Items] | ||
Total revenues | $ 8,773 | $ 5,154 |
United States | ||
Disaggregation Of Revenue [Line Items] | ||
Total revenues | 6,511 | 3,194 |
Asia | ||
Disaggregation Of Revenue [Line Items] | ||
Total revenues | 860 | 890 |
Europe | ||
Disaggregation Of Revenue [Line Items] | ||
Total revenues | 737 | 623 |
Outside U.S | ||
Disaggregation Of Revenue [Line Items] | ||
Total revenues | 225 | 142 |
Middle East | ||
Disaggregation Of Revenue [Line Items] | ||
Total revenues | 338 | 194 |
Other | ||
Disaggregation Of Revenue [Line Items] | ||
Total revenues | $ 102 | $ 111 |
Revenue Recognition - Summary_2
Revenue Recognition - Summary of Receivables and Deferred Revenue from Contracts with Customers (Details) - USD ($) $ in Thousands | 3 Months Ended | ||
Mar. 31, 2019 | Jan. 01, 2019 | Dec. 31, 2018 | |
Balances from contracts with customers only: | |||
Accounts receivable | $ 10,973 | $ 10,206 | $ 4,725 |
Deferred revenue | 800 | ||
Revenue recognized in the period relating to: | |||
The beginning deferred revenue balance | $ 407 |
Revenue Recognition - Additiona
Revenue Recognition - Additional Information (Details1) $ in Thousands | Mar. 31, 2019USD ($) |
Disaggregation Of Revenue [Line Items] | |
Revenue performance obligation expected to recognized period | $ 670 |
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date: 2020-03-31 | |
Disaggregation Of Revenue [Line Items] | |
Revenue performance obligation expected to recognized period | $ 21 |
Revenue performance obligation expected to recognized period | 1 year |
Revenue Recognition - Additio_2
Revenue Recognition - Additional Information (Details) | 3 Months Ended |
Mar. 31, 2019USD ($) | |
Revenues [Abstract] | |
Revenue performance obligation expected to recognized period | $ 670,000 |
Transaction price allocated to extended warranty service contracts | 115,000 |
Capitalized contract cost | 254,000 |
Capitalized contract cost current | 160,000 |
Capitalized contract cost non current | 94,000 |
Capitalized contract cost amortization | 49,000 |
Capitalized contract cost impairments | $ 0 |
Revenue Recognition - Summary_3
Revenue Recognition - Summary of Adjustment to Accounts on the Condensed Balance Sheet (Details) - USD ($) $ in Thousands | Mar. 31, 2019 | Jan. 01, 2019 | Dec. 31, 2018 | Mar. 31, 2018 | Dec. 31, 2017 |
ASSETS | |||||
Accounts receivable | $ 10,973 | $ 10,206 | $ 4,725 | ||
Prepaid expenses and other current assets | 3,116 | 2,097 | 1,919 | ||
Total current assets | 83,371 | 26,331 | 20,672 | ||
Other assets | 380 | 416 | 291 | ||
Total Assets | 85,749 | 31,651 | 25,867 | ||
Liabilities and Stockholders' Equity (Deficit) | |||||
Accrued expenses and other current liabilities | 5,134 | 5,366 | 5,366 | ||
Deferred revenue | 779 | 800 | 688 | ||
Total current liabilities | 8,684 | 8,542 | 8,430 | ||
Accumulated deficit | (184,803) | (176,450) | (182,122) | ||
Total stockholders' equity (deficit) | 56,272 | (67,916) | (73,588) | $ (55,694) | $ (49,520) |
Total Liabilities and Stockholders' Equity (Deficit) | 85,749 | 31,651 | $ 25,867 | ||
Adjustments [Member] | |||||
ASSETS | |||||
Accounts receivable | (2,694) | 5,481 | |||
Prepaid expenses and other current assets | (160) | 178 | |||
Total current assets | (2,854) | 5,659 | |||
Other assets | (94) | 125 | |||
Total Assets | (2,948) | 5,784 | |||
Liabilities and Stockholders' Equity (Deficit) | |||||
Accrued expenses and other current liabilities | 20 | ||||
Deferred revenue | (107) | 112 | |||
Total current liabilities | (87) | 112 | |||
Accumulated deficit | (2,861) | 5,672 | |||
Total stockholders' equity (deficit) | (2,861) | 5,672 | |||
Total Liabilities and Stockholders' Equity (Deficit) | (2,948) | $ 5,784 | |||
Pro forma [Member] | |||||
ASSETS | |||||
Accounts receivable | 8,279 | ||||
Prepaid expenses and other current assets | 2,956 | ||||
Total current assets | 80,517 | ||||
Other assets | 286 | ||||
Total Assets | 82,801 | ||||
Liabilities and Stockholders' Equity (Deficit) | |||||
Accrued expenses and other current liabilities | 5,154 | ||||
Deferred revenue | 672 | ||||
Total current liabilities | 8,597 | ||||
Accumulated deficit | (187,664) | ||||
Total stockholders' equity (deficit) | 53,411 | ||||
Total Liabilities and Stockholders' Equity (Deficit) | $ 82,801 |
Revenue Recognition - Summary_4
Revenue Recognition - Summary of Significant Changes on Condensed Statement of Operations (Details) - USD ($) $ / shares in Units, $ in Thousands | 3 Months Ended | |
Mar. 31, 2019 | Mar. 31, 2018 | |
Disaggregation Of Revenue [Line Items] | ||
Revenue (including related party activity of $580 and $512 for the three months ended March 31, 2019 and 2018, respectively) | $ 8,773 | $ 5,154 |
Gross profit | 6,489 | 2,536 |
Selling, general and administrative | 10,221 | 5,288 |
Total operating expenses | 14,506 | 8,242 |
Loss from operations | (8,017) | (5,706) |
Net loss | $ (8,353) | $ (6,634) |
Net loss per share of common stock, basic and diluted | $ (1) | $ (4.85) |
ASC 606 | Adjustments [Member] | ||
Disaggregation Of Revenue [Line Items] | ||
Revenue (including related party activity of $580 and $512 for the three months ended March 31, 2019 and 2018, respectively) | $ 2,783 | |
Gross profit | 2,783 | |
Selling, general and administrative | (28) | |
Total operating expenses | (28) | |
Loss from operations | 2,811 | |
Net loss | $ 2,811 | |
Net loss per share of common stock, basic and diluted | $ 0.34 | |
ASC 606 | Pro forma [Member] | ||
Disaggregation Of Revenue [Line Items] | ||
Revenue (including related party activity of $580 and $512 for the three months ended March 31, 2019 and 2018, respectively) | $ 11,556 | |
Gross profit | 9,272 | |
Selling, general and administrative | 10,193 | |
Total operating expenses | 14,478 | |
Loss from operations | (5,206) | |
Net loss | $ (5,542) | |
Net loss per share of common stock, basic and diluted | $ (0.66) |
Revenue Recognition - Summary_5
Revenue Recognition - Summary of Significant Changes on Condensed Statement of Cash Flow (Details) - USD ($) $ in Thousands | 3 Months Ended | |
Mar. 31, 2019 | Mar. 31, 2018 | |
Disaggregation Of Revenue [Line Items] | ||
Net loss | $ (8,353) | $ (6,634) |
Adjustments to reconcile net loss to net cash used in operating activities: | ||
Accounts receivable | (752) | (403) |
Prepaid expenses and other current assets | (1,019) | 628 |
Accounts payable and accrued expenses | 341 | 489 |
Deferred revenue | (12) | 71 |
Other non-current assets and liabilities | 48 | 17 |
Net cash used in operating activities | (8,547) | $ (5,072) |
ASC 606 | Adjustments [Member] | ||
Disaggregation Of Revenue [Line Items] | ||
Net loss | 2,811 | |
Adjustments to reconcile net loss to net cash used in operating activities: | ||
Accounts receivable | (2,787) | |
Prepaid expenses and other current assets | (18) | |
Accounts payable and accrued expenses | 20 | |
Deferred revenue | 5 | |
Other non-current assets and liabilities | (31) | |
ASC 606 | Pro forma [Member] | ||
Disaggregation Of Revenue [Line Items] | ||
Net loss | (5,542) | |
Adjustments to reconcile net loss to net cash used in operating activities: | ||
Accounts receivable | (3,539) | |
Prepaid expenses and other current assets | (1,037) | |
Accounts payable and accrued expenses | 361 | |
Deferred revenue | (7) | |
Other non-current assets and liabilities | 17 | |
Net cash used in operating activities | $ (8,547) |
Condensed Balance Sheet Compo_3
Condensed Balance Sheet Components - Schedule of Inventories (Details) - USD ($) $ in Thousands | Mar. 31, 2019 | Dec. 31, 2018 |
Inventory Disclosure [Abstract] | ||
Raw materials | $ 2,534 | $ 2,688 |
Finished goods | 1,939 | 1,571 |
Total inventories | $ 4,473 | $ 4,259 |
Condensed Balance Sheet Compo_4
Condensed Balance Sheet Components - Schedule of Prepaid Expenses and Other Current Assets (Details) - USD ($) $ in Thousands | Mar. 31, 2019 | Jan. 01, 2019 | Dec. 31, 2018 |
Prepaid Expense And Other Assets Current [Abstract] | |||
Prepaid suppliers | $ 449 | $ 503 | |
Prepaid rent | 112 | 107 | |
Prepaid insurance | 994 | 65 | |
Prepaid prescription drug user fee | 310 | 465 | |
Prepaid license fees | 321 | 226 | |
Prepaid clinical studies | 174 | 154 | |
Prepaid other expenses | 756 | 399 | |
Total prepaid expenses and other current assets | $ 3,116 | $ 2,097 | $ 1,919 |
Condensed Balance Sheet Compo_5
Condensed Balance Sheet Components - Schedule of Equipment and Furniture, Net (Details) - USD ($) $ in Thousands | Mar. 31, 2019 | Dec. 31, 2018 |
Property Plant And Equipment [Line Items] | ||
Equipment and furniture, gross | $ 3,503 | $ 3,406 |
Less: accumulated depreciation | (2,056) | (1,882) |
Equipment and furniture, net | 1,447 | 1,524 |
Machinery and Lab Equipment | ||
Property Plant And Equipment [Line Items] | ||
Equipment and furniture, gross | 1,529 | 1,478 |
Medical Devices | ||
Property Plant And Equipment [Line Items] | ||
Equipment and furniture, gross | 939 | 929 |
Computer Software | ||
Property Plant And Equipment [Line Items] | ||
Equipment and furniture, gross | 238 | 215 |
Office Furniture And Equipment | ||
Property Plant And Equipment [Line Items] | ||
Equipment and furniture, gross | 424 | 423 |
Computer Hardware | ||
Property Plant And Equipment [Line Items] | ||
Equipment and furniture, gross | $ 373 | $ 361 |
Condensed Balance Sheet Compo_6
Condensed Balance Sheet Components - Additional information (Details) - USD ($) $ in Thousands | 3 Months Ended | |
Mar. 31, 2019 | Mar. 31, 2018 | |
Balance Sheet Related Disclosures [Abstract] | ||
Depreciation expense | $ 174 | $ 169 |
Condensed Balance Sheet Compo_7
Condensed Balance Sheet Components - Components of Accrued Expenses and Other Current Liabilities (Details) - USD ($) $ in Thousands | Mar. 31, 2019 | Dec. 31, 2018 |
Accrued Liabilities And Other Liabilities [Abstract] | ||
Accrued compensation | $ 1,870 | $ 2,836 |
Accrued warranty | 122 | 158 |
Accrued inventory | 115 | 33 |
Accrued professional services | 1,760 | 1,421 |
Accrued reimbursement hub costs | 731 | 264 |
Accrued sales tax | 65 | 75 |
Accrued other | 471 | 579 |
Total accrued expenses and other current liabilities | $ 5,134 | $ 5,366 |
Fair Value Measurements - Sched
Fair Value Measurements - Schedule of Assets and Liabilities Measured at Fair Value on Recurring Basis (Details) - USD ($) $ in Thousands | Mar. 31, 2019 | Dec. 31, 2018 |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] | ||
Total assets at fair value | $ 63,342 | $ 8,164 |
Total liabilities at fair value | 197 | 2,206 |
Warrant Liability | ||
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] | ||
Total liabilities at fair value | 1,800 | |
Cash Equivalents | ||
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] | ||
Total assets at fair value | 63,342 | 8,164 |
Derivative Liability | ||
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] | ||
Total liabilities at fair value | 197 | 406 |
Quoted Prices in Active Markets (Level 1) | ||
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] | ||
Total assets at fair value | 63,342 | 8,164 |
Quoted Prices in Active Markets (Level 1) | Cash Equivalents | ||
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] | ||
Total assets at fair value | 63,342 | 8,164 |
Significant Unobservable Inputs (Level 3) | ||
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] | ||
Total liabilities at fair value | 197 | 2,206 |
Significant Unobservable Inputs (Level 3) | Warrant Liability | ||
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] | ||
Total liabilities at fair value | 1,800 | |
Significant Unobservable Inputs (Level 3) | Derivative Liability | ||
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] | ||
Total liabilities at fair value | $ 197 | $ 406 |
Fair Value Measurements - Addit
Fair Value Measurements - Additional Information (Details) $ in Thousands | Mar. 31, 2019USD ($) | Dec. 31, 2018USD ($) |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] | ||
Cash equivalents | $ 63,342 | $ 8,164 |
Valuation Technique, Discounted Cash Flow | Derivative Liability | Discount Rate | ||
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] | ||
Fair value assumption, measurement input | 0.17 | |
Valuation Technique, Discounted Cash Flow | Derivative Liability | Timing of Change in Control Event, March 19, 2020 | ||
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] | ||
Fair value assumption, measurement input | 0.05 | |
Valuation Technique, Discounted Cash Flow | Derivative Liability | Timing of Change in Control Event, March 19, 2021 | ||
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] | ||
Fair value assumption, measurement input | 0.10 | |
Cash Equivalents | ||
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] | ||
Cash equivalents | $ 63,342 | $ 8,164 |
Fair Value Measurements - Sch_2
Fair Value Measurements - Schedule of Weighted-Average Assumptions Used to Determine Fair Value (Details) - 2015 and 2017 Preferred Warrants | Mar. 31, 2019 | Mar. 31, 2018 |
Risk-Free Interest Rate | Minimum | ||
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] | ||
Warrants, fair value assumption, measurement input | 0.025 | 0.026 |
Risk-Free Interest Rate | Maximum | ||
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] | ||
Warrants, fair value assumption, measurement input | 0.026 | 0.027 |
Expected Volatility | Minimum | ||
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] | ||
Warrants, fair value assumption, measurement input | 0.602 | 0.580 |
Expected Volatility | Maximum | ||
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] | ||
Warrants, fair value assumption, measurement input | 0.614 | 0.613 |
Expected Term | Minimum | ||
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] | ||
Warrants, fair value assumption, expected term | 5 years 7 months 6 days | 6 years 6 months |
Expected Term | Maximum | ||
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] | ||
Warrants, fair value assumption, expected term | 8 years 1 month 6 days | 9 years |
Expected Dividend Yield | ||
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] | ||
Warrants, fair value assumption, measurement input | 0 | 0 |
Fair Value Measurements - Sch_3
Fair Value Measurements - Schedule of Change in the Fair Value of Liability (Details) - Significant Unobservable Inputs (Level 3) $ in Thousands | 3 Months Ended |
Mar. 31, 2019USD ($) | |
Derivative Liability | |
Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items] | |
Balance at December 31, 2018 | $ 406 |
Change in fair value of warrant liability | (209) |
Balance at March 31, 2019 | 197 |
Warrant Liability | |
Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items] | |
Balance at December 31, 2018 | 1,800 |
Change in fair value of warrant liability | 35 |
Reclassification of a warrant liability to equity | $ (1,835) |
Long-term Debt - Summary of Lon
Long-term Debt - Summary of Long-Term Debt, Net (Details) - USD ($) $ in Thousands | Mar. 31, 2019 | Dec. 31, 2018 |
Debt Disclosure [Abstract] | ||
Principal amount outstanding | $ 20,000 | $ 20,000 |
PIK Interest | 801 | 657 |
Unamortized discount | (464) | (495) |
Unamortized issue costs | (209) | (223) |
Net carrying amount | $ 20,128 | $ 19,939 |
Long-term Debt - Additional Inf
Long-term Debt - Additional Information (Details) - 2017 Credit Agreement - USD ($) | 3 Months Ended | |
Mar. 31, 2019 | Dec. 31, 2018 | |
Debt Instrument [Line Items] | ||
Outstanding debt | $ 20,000,000 | $ 20,000,000 |
Credit agreement maturity date | Mar. 20, 2022 | |
Interest rate (in percentage) | 10.00% | |
Accrued interest percentage | 1.00% | |
Credit facility minimum liquidity required for covenants compliance | $ 3,000,000 | |
Credit facility, covenant description | The Company’s obligations under the 2017 Credit Agreement are secured by a security interest in substantially all of its assets. Other than a minimum liquidity requirement of $3,000, there are no financial covenants contained in the 2017 Credit Agreement and the Company is in compliance with the affirmative and restrictive covenants as of March 31, 2019 | |
LIBOR | ||
Debt Instrument [Line Items] | ||
Spread on variable rate basis | three-month |
Capitalization - Additional Inf
Capitalization - Additional Information (Details) - $ / shares | Feb. 19, 2019 | Mar. 31, 2019 | Dec. 31, 2018 | Mar. 31, 2018 |
Class Of Stock [Line Items] | ||||
Common stock, shares authorized | 200,000,000 | 66,905,000 | ||
Preferred Stock, Shares Authorized | 10,000,000 | 0 | ||
Common stock, par value per share | $ 0.00001 | $ 0.00001 | $ 0.00001 | |
Preferred stock, par value per share | $ 0.00001 | $ 0.00001 | ||
IPO | ||||
Class Of Stock [Line Items] | ||||
Common stock issued and sold | 10,635,894 | |||
Shares authorized | 210,000,000 | |||
Common stock, shares authorized | 200,000,000 | |||
Preferred Stock, Shares Authorized | 10,000,000 | |||
Common stock, par value per share | $ 0.00001 | |||
Preferred stock, par value per share | $ 0.00001 |
Capitalization - Summary of Sha
Capitalization - Summary of Shares of Common Stock Reserved for Future Issuance (Details) - shares | Mar. 31, 2019 | Dec. 31, 2018 |
Class Of Stock [Line Items] | ||
Number of shares of common stock reserved for future issuance | 6,287,273 | 13,452,992 |
Employee Stock Purchase Plan | ||
Class Of Stock [Line Items] | ||
Number of shares of common stock reserved for future issuance | 350,000 | |
Conversion of Series AA convertible preferred stock | ||
Class Of Stock [Line Items] | ||
Number of shares of common stock reserved for future issuance | 7,161,719 | |
Conversion of Series BB convertible preferred stock | ||
Class Of Stock [Line Items] | ||
Number of shares of common stock reserved for future issuance | 1,332,708 | |
Conversion of Series CC convertible preferred stock | ||
Class Of Stock [Line Items] | ||
Number of shares of common stock reserved for future issuance | 2,141,467 | |
Options to Purchase Common Stock | ||
Class Of Stock [Line Items] | ||
Number of shares of common stock reserved for future issuance | 3,126,728 | 2,490,767 |
Vesting of Restricted Stock Units to Common Stock | ||
Class Of Stock [Line Items] | ||
Number of shares of common stock reserved for future issuance | 17,630 | 18,522 |
Remaining Shares Available for Issuance | ||
Class Of Stock [Line Items] | ||
Number of shares of common stock reserved for future issuance | 2,592,095 | 104,828 |
Warrants to Purchase Convertible Preferred Stock | ||
Class Of Stock [Line Items] | ||
Number of shares of common stock reserved for future issuance | 174,032 | |
Warrants to Purchase Common Stock | ||
Class Of Stock [Line Items] | ||
Number of shares of common stock reserved for future issuance | 200,820 | 28,949 |
Warrants - Summary of the Warra
Warrants - Summary of the Warrants Outstanding (Details) - shares | Mar. 31, 2019 | Dec. 31, 2018 |
Warrants Issued in 2015 and Exercisable for Common Stock through November 5, 2021 | ||
Class Of Warrant Or Right [Line Items] | ||
Warrants outstanding | 26,788 | 28,949 |
Warrants Issued in 2015 and Exercisable for Common Stock through September 11, 2024 | ||
Class Of Warrant Or Right [Line Items] | ||
Warrants outstanding | 67,415 | |
Warrants Issued in 2017 and Exercisable for Common Stock through March 20, 2027 | ||
Class Of Warrant Or Right [Line Items] | ||
Warrants outstanding | 106,617 | |
Warrants Issued in 2015 and Exercisable for Series AA Convertible Preferred Stock through September 11, 2024 | ||
Class Of Warrant Or Right [Line Items] | ||
Warrants outstanding | 67,415 | |
Warrants Issued in 2017 and Exercisable for Series AA Convertible Preferred Stock through March 20, 2027 | ||
Class Of Warrant Or Right [Line Items] | ||
Warrants outstanding | 106,617 |
Warrants - Summary of the War_2
Warrants - Summary of the Warrants Outstanding (Parenthetical) (Details) - $ / shares | Mar. 31, 2019 | Dec. 31, 2018 |
Warrants Issued in 2015 and Exercisable for Common Stock through November 5, 2021 | ||
Class Of Warrant Or Right [Line Items] | ||
Warrants exercise price | $ 0.05 | $ 0.05 |
Warrants and Rights Outstanding, Maturity Date | Nov. 5, 2021 | Nov. 5, 2021 |
Warrants Issued in 2015 and Exercisable for Common Stock through September 11, 2024 | ||
Class Of Warrant Or Right [Line Items] | ||
Warrants exercise price | $ 4.45 | |
Warrants and Rights Outstanding, Maturity Date | Sep. 11, 2024 | |
Warrants Issued in 2017 and Exercisable for Common Stock through March 20, 2027 | ||
Class Of Warrant Or Right [Line Items] | ||
Warrants exercise price | $ 4.45 | |
Warrants and Rights Outstanding, Maturity Date | Mar. 20, 2027 | |
Warrants Issued in 2015 and Exercisable for Series AA Convertible Preferred Stock through September 11, 2024 | ||
Class Of Warrant Or Right [Line Items] | ||
Warrants exercise price | $ 4.45 | |
Warrants and Rights Outstanding, Maturity Date | Sep. 11, 2024 | |
Warrants Issued in 2017 and Exercisable for Series AA Convertible Preferred Stock through March 20, 2027 | ||
Class Of Warrant Or Right [Line Items] | ||
Warrants exercise price | $ 4.45 | |
Warrants and Rights Outstanding, Maturity Date | Mar. 20, 2027 |
Share-Based Compensation - Addi
Share-Based Compensation - Additional Information (Details) | Feb. 19, 2019 | Mar. 31, 2019USD ($)shares | Jan. 31, 2018shares | Mar. 31, 2019USD ($)Installmentshares | Mar. 31, 2018USD ($) | Dec. 31, 2018shares |
Share Based Compensation Arrangement By Share Based Payment Award [Line Items] | ||||||
Number of shares of common stock reserved for future issuance | 6,287,273 | 6,287,273 | 13,452,992 | |||
Restricted Stock Units | ||||||
Share Based Compensation Arrangement By Share Based Payment Award [Line Items] | ||||||
Unrecognized compensation expense period | 3 years 10 months 24 days | |||||
Vesting period | 3 years | 2 years | ||||
Awards vesting date | Feb. 1, 2018 | Mar. 1, 2020 | ||||
Number of equal installments | Installment | 8 | |||||
Share-based compensation expense | $ | $ 36,675,000 | $ 0 | ||||
Unrecognized compensation expense related to restricted stock units | $ | $ 174,000 | $ 174,000 | ||||
Restricted Stock Units | Executives | ||||||
Share Based Compensation Arrangement By Share Based Payment Award [Line Items] | ||||||
Number of shares available for grant | 13,000 | 18,522 | ||||
Restricted Stock Units | First Anniversary | ||||||
Share Based Compensation Arrangement By Share Based Payment Award [Line Items] | ||||||
Vesting percentage | 25.00% | 50.00% | ||||
Restricted Stock Units | After First Anniversary | ||||||
Share Based Compensation Arrangement By Share Based Payment Award [Line Items] | ||||||
Vesting percentage | 25.00% | 50.00% | ||||
Restricted Stock Units | After Second Anniversary | ||||||
Share Based Compensation Arrangement By Share Based Payment Award [Line Items] | ||||||
Vesting percentage | 25.00% | |||||
Employee Stock Purchase Plan | ||||||
Share Based Compensation Arrangement By Share Based Payment Award [Line Items] | ||||||
Number of shares of common stock reserved for future issuance | 350,000 | 350,000 | ||||
2019 Equity Incentive Plan | ||||||
Share Based Compensation Arrangement By Share Based Payment Award [Line Items] | ||||||
Number of shares of common stock reserved for future issuance | 2,500,000 | 2,500,000 | ||||
Period for which number of shares available for issuance automatically increase | 10 years | |||||
Percentage of automatic increase in shares of common stock reserved for issuance | 4.00% | 4.00% | ||||
Unrecognized compensation expense related to outstanding options | $ | $ 6,086,000 | $ 6,086,000 | ||||
Unrecognized compensation expense period | 2 years 3 months 18 days | |||||
2019 Equity Incentive Plan | Employee Stock Purchase Plan | ||||||
Share Based Compensation Arrangement By Share Based Payment Award [Line Items] | ||||||
Maximum number of common stock shares issued | 350,000 | 350,000 | ||||
Common stock shares reserved for issuance annual increase percentage | 1.00% | 1.00% | ||||
Common stock shares reserved for issuance annual increase | 500,000 |
Share-Based Compensation - Sche
Share-Based Compensation - Schedule of Stock Option Activity (Details) - USD ($) $ / shares in Units, $ in Thousands | 3 Months Ended | 12 Months Ended |
Mar. 31, 2019 | Dec. 31, 2018 | |
Share Based Compensation [Abstract] | ||
Number of options outstanding at beginning of the period | 2,490,767 | |
Number of options granted | 664,598 | |
Number of options exercised | (2,985) | |
Number of options forfeited/cancelled | (25,652) | |
Number of options outstanding at end of the period | 3,126,728 | 2,490,767 |
Number of options vested and expected to vest at the end of the period | 3,126,728 | |
Number of options exercisable at the end of the period | 1,234,741 | |
Average exercise price outstanding | $ 4.92 | $ 2.83 |
Average exercise price granted | 12.69 | |
Average exercise price exercised | 2.61 | |
Average exercise price forfeited/cancelled | 2.69 | |
Average exercise price vested and expected to vest at the end of the period | 4.92 | |
Average exercise price exercisable at the end of the period | $ 2.83 | |
Remaining contractual term outstanding at beginning of the period | 8 years 9 months 18 days | 8 years 8 months 12 days |
Remaining contractual term vested and expected to vest at the end of the period | 8 years 9 months 18 days | |
Remaining contractual term exercisable at the end of the period | 8 years 1 month 6 days | |
Aggregate intrinsic value outstanding at beginning of the period | $ 1,335 | $ 25,111 |
Average intrinsic value vested and expected to vest at the end of the period | 1,335 | |
Average intrinsic value exercisable at the end of the period | $ 1,011 |
Share-Based Compensation - Summ
Share-Based Compensation - Summary of Stock Options Granted and Exercised (Details) - USD ($) $ / shares in Units, $ in Thousands | 3 Months Ended | |
Mar. 31, 2019 | Mar. 31, 2018 | |
Share Based Compensation [Abstract] | ||
Weighted-average grant date fair value per share of option grants | $ 7.37 | $ 1.22 |
Aggregate intrinsic value of options exercised | $ 4 | $ 31 |
Share-Based Compensation - Su_2
Share-Based Compensation - Summary of Stock-based Compensation Expense (Details) - Employee Stock Option - USD ($) $ in Thousands | 3 Months Ended | |
Mar. 31, 2019 | Mar. 31, 2018 | |
Share Based Compensation Arrangement By Share Based Payment Award [Line Items] | ||
Stock-based compensation expense | $ 1,250 | $ 406 |
Cost of Goods Sold | ||
Share Based Compensation Arrangement By Share Based Payment Award [Line Items] | ||
Stock-based compensation expense | 33 | 13 |
Selling, General and Administrative | ||
Share Based Compensation Arrangement By Share Based Payment Award [Line Items] | ||
Stock-based compensation expense | 1,010 | 337 |
Research and Development | ||
Share Based Compensation Arrangement By Share Based Payment Award [Line Items] | ||
Stock-based compensation expense | $ 207 | $ 56 |
Share-Based Compensation - Sc_2
Share-Based Compensation - Schedule of Weighted Average Fair Value of Stock Option Granted (Details) | 3 Months Ended | |
Mar. 31, 2019 | Mar. 31, 2018 | |
Share Based Compensation Arrangement By Share Based Payment Award [Line Items] | ||
Expected dividend yield | 0.00% | |
Employee Stock Option | ||
Share Based Compensation Arrangement By Share Based Payment Award [Line Items] | ||
Risk-free interest rate | 2.60% | 2.50% |
Expected volatility | 61.30% | 58.00% |
Expected term (in years) | 6 years | 5 years 7 months 6 days |
Expected dividend yield | 0.00% | 0.00% |
Net Loss Per Share - Anti-Dilut
Net Loss Per Share - Anti-Dilutive Securities Excluded from Calculation of Diluted Net Loss per Share (Details) - shares | 3 Months Ended | 12 Months Ended |
Mar. 31, 2019 | Dec. 31, 2018 | |
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items] | ||
Antidilutive securities excluded from computation of diluted weighted average shares | 3,345,178 | 13,348,164 |
Series AA Convertible Preferred Stock | ||
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items] | ||
Antidilutive securities excluded from computation of diluted weighted average shares | 7,161,719 | |
Series BB Convertible Preferred Stock | ||
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items] | ||
Antidilutive securities excluded from computation of diluted weighted average shares | 1,332,708 | |
Series CC Convertible Preferred Stock | ||
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items] | ||
Antidilutive securities excluded from computation of diluted weighted average shares | 2,141,467 | |
Employee Stock Option | ||
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items] | ||
Antidilutive securities excluded from computation of diluted weighted average shares | 3,126,728 | 2,490,767 |
Restricted Stock Units | ||
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items] | ||
Antidilutive securities excluded from computation of diluted weighted average shares | 17,630 | 18,522 |
Outstanding Series AA Convertible Preferred Stock Warrants | ||
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items] | ||
Antidilutive securities excluded from computation of diluted weighted average shares | 174,032 | |
Outstanding Common Stock Warrants | ||
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items] | ||
Antidilutive securities excluded from computation of diluted weighted average shares | 200,820 | 28,949 |
Related Party Transactions - Ad
Related Party Transactions - Additional Information (Details) - USD ($) $ in Thousands | 3 Months Ended | ||
Mar. 31, 2019 | Mar. 31, 2018 | Dec. 31, 2018 | |
Related Party Transaction [Line Items] | |||
Revenue from related parties | $ 580 | $ 512 | |
Due from related parties current | 645 | $ 573 | |
Stockholder | |||
Related Party Transaction [Line Items] | |||
Revenue from related parties | 469 | 498 | |
Due from related parties current | 469 | 561 | |
Stockholder and Employee | |||
Related Party Transaction [Line Items] | |||
Revenue from related parties | 111 | 14 | |
Due from related parties current | $ 176 | $ 12 |